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SUMMARY 
Vitamin D plays an important role in calcium homeostasis and bone metabolism, and it is able to 
modulate proliferation and differentiation of cells, cardiovascular function and also innate and adaptive 
immune function. The active form of vitamin D (vitamin D3, 1,25(OH)2D), exerts most of its effects 
through the vitamin D receptor (VDR). Indeed, in recent years the interest in vitamin D’s studies is 
increased, especially due to the presence of its receptor in many tissues and organs. VDR forms a 
heterodimer with the retinoid X receptor (RXR) upon stimulation by 1,25(OH)2D. In turn, VDR/RXR 
binds to DNA sequences termed “vitamin D response elements” in target genes, regulating gene 
transcription. In order to exert its biological effects, VDR signaling interacts with other intracellular 
signaling pathways. Sometimes, vitamin D exerts its biological effects without regulating either gene 
expression or protein synthesis. Although the regulatory role of vitamin D in many biological processes 
is well understood yet, many studies indicate that the role of vitamin D is not limited to regulation of 
bone and mineral homeostasis, but it is also important for its extraskeletal actions. Indeed, it has become 
the major driving force behind the significant increase in research articles on vitamin D published over 
the past several decades.  
For this reason, this research aimed to examine the role of vitamin D signaling in a number of 
extraskeletal tissues (ovarian, gastric, cardiac and brain), and to assess the feasibility of translating these 
findings into treatments of human diseases affecting those extracellular tissues. 
It has been demonstrated that in ovarian tissues a high density of VDR is present as well and vitamin 
D3 acts through intracellular mechanisms similar to what observed for resveratrol, a natural antioxidant 
polyphenol able to exert a wide range of biological effect on several tissues. The aims of this research 
were to evaluate the cooperative effects of resveratrol combined with vitamin D3 on CHO-K1 cells 
studying cell viability, ROS production, activated pathways in in vitro study and in in vivo study to 
quantify vitamin D3 and resveratrol, to analyze the concentration of radical oxygen species and to study 
activated pathways. Moreover, the modulation of specific intracellular pathways involving ER and 
VDR receptors has been studied. Results show that both in in vitro and in in vivo experiments, 
resveratrol exerts a greater effect when administered in combination with vitamin D3. In particular, the 
role of vitamin D3 in maintaining and supporting the biological activity of resveratrol has been clearly 
observed. Moreover, resveratrol plus vitamin D3 in blood concentrations showed a biphasic absorption 
rate. Such results could be used as a fundamental data for the development of new therapies for 
gynecological conditions, such as hot-flashes. 
Another widespread problem is the abnormal use of nonsteroidal anti-inflammatory drugs in order to 
reduce pain. There is a high risk of developing gastric and enteric damages. These patients usually 
receive anti-acid treatment, but a number of clinical studies provided evidence of the ineffectiveness of 
proton-pump inhibitors. Vitamin D, on the other hand, appears to have high preventive and therapeutic 
potential. Recently, it has been introduced a commercial product that, in addition to anti-acid properties 
of alginates, claims to possess gastroprotective properties deriving from vitamin D3 and from plant 
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extracts. In this research the effectiveness of vitamin D3 combined with alginates to prevent the damage 
induced in cultured gastric cells by Diclofenac during acidic or hyperacidic exposition have been studied 
measuring cell viability, radical oxygen species production along with apoptotic and survival pathways. 
Analyzing the effects on cardiac tissue, the study demonstrate that vitamin D3 has a cooperative effect 
with Q10 and L-arginine on both cardiac and endothelial cells to prevent the damage of ischemic 
condition. In particular, the effects of vitamin D3, Q10 and L-arginine alone or combined on cell 
viability, nitric oxide and reactive oxygen species productions in endothelial and cardiac cells were 
studied. Moreover, the involvement of  PI3K/Akt and ERK/MAPK pathways leading to eNOS 
activation as well as the involvement of vitamin D receptor were also investigated. The same agents 
were tested in an animal model to verify vasodilation, nitric oxide and reactive oxygen species 
production. The data obtained demonstrate for the first time the beneficial and cooperative effect of 
stimulation with vitamin D3, Q10 and L-arginine. Indeed, in cardiac and endothelial cells, vitamin D3, 
Q10 and L-arginine combined were able to induce a nitric oxide production higher than the that induced 
by the 3 substances alone. The effects on vasodilation induced by cooperative stimulation have been 
confirmed in an in vivo model as well. The use of a combination of vitamin D3, Q10 and L-arginine to 
counteract increased free radical production could be a potential method to reduce myocardial injury or 
the effects of aging on the heart. 
As regards the research focused on vitamin D3 in brain ageing, the ability of vitamin D3 combined with 
lipoic acid to prevent or repair the damage caused by oxidative stress and iron accumulation, two 
different biological aspects involved in brain ageing and neurodegeneration, has been studied in 
astrocytes. Cell viability, mitochondrial membrane potential and pathways activated in oxidative 
condition have been investigated. In addition, catalytic iron was used to assess the protection exerted 
by the combination of vitamin D3 and lipoic acid in induced neurodegeneration. In these experiments, 
cell viability, ROS production, iron concentration and activation of intracellular pathways have been 
studied. In this research, the combination of vitamin D3 and lipoic acid showed beneficial effects on 
viability of astrocytes, since the substances are able to cross the brain barrier. In addition, vitamin D3 
plus lipoic acid was able to attenuate the H2O2-induced apoptosis through the mitochondrial-mediated 
pathway. The combination was also able to counteract the adverse effects caused by iron, preventing its 
accumulation. All these data support the hypothesis of a cooperative activity exerted by vitamin D3 and 
lipoic acid in astrocytes, indicating a possible new strategy to slow down brain ageing.  
Therefore, the ability of vitamin D3 and lipoic acid to counteract brain aging has resulted in the creation 
of a commercial product, Cebral®. 
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RIASSUNTO  
La vitamina D svolge un ruolo fondamentale nell'omeostasi del calcio e nel metabolismo osseo, modula 
la proliferazione e la differenziazione cellulare, l’immunità innata ed adattativa e contribuisce a regolare 
la funzione cardiovascolare. La forma attiva della vitamina D (vitamina D3, 1,25 (OH) 2D), esercita la 
maggior parte dei suoi effetti attraverso l’interazione con il suo recettore specifico (VDR). Negli ultimi 
anni l'interesse nello studio della vitamina D è aumentato, vista la presenza del suo recettore in molti 
organi e tessuti. VDR forma un eterodimero con il recettore X retinoide (RXR) dopo il legame con la 
vitamina D3. A sua volta, VDR/RXR si lega alle sequenze di DNA chiamate “elementi responsivi alla 
vitamina D” nei geni bersaglio, regolando la trascrizione genica. Al fine di esercitare i suoi effetti 
biologici, la segnalazione innescata da VDR interagisce con altre vie di segnalazione intracellulari. 
Sebbene il suo ruolo regolatorio in molti processi biologici sia ben noto, molti studi indicano che il 
ruolo della vitamina D non si limita alla regolazione dell'omeostasi ossea e minerale, ma è anche 
importante per le sue azioni extrascheletriche. Per questo motivo, questo studio è andato ad indagare il 
ruolo della segnalazione della vitamina D in numerosi tessuti extrascheletrici (ovarico, gastrico, 
cardiaco e cerebrale) per valutare la traslazionalità di questi risultati in trattamenti di malattie che 
colpiscono l’uomo. È stato dimostrato che nei tessuti ovarici è presente un'alta densità di VDR e la 
vitamina D3 agisce attraverso meccanismi intracellulari simili a quelli osservati per il resveratrolo, un 
polifenolo antiossidante naturale in grado di esercitare una vasta gamma di effetti biologici su diversi 
tessuti. Gli obiettivi di questa ricerca sono stati valutare gli effetti cooperativi del resveratrolo combinato 
con la vitamina D3 su cellule CHO-K1 (cellule ovariche) studiando la vitalità cellulare, la produzione 
di ROS, i percorsi attivati in vitro ed in vivo, la quantificazione di vitamina D3 e resveratrolo. Inoltre, è 
stata studiata la modulazione di specifici pathways intracellulari che coinvolgono i recettori ER e VDR. 
I risultati mostrano che sia in esperimenti in vitro, sia in vivo, il resveratrolo esercita un effetto maggiore 
quando somministrato in combinazione con vitamina D3. In particolare, è stato chiaramente osservato 
il ruolo della vitamina D3 nel mantenimento e nel supporto dell'attività biologica del resveratrolo. 
Inoltre, il resveratrolo più la vitamina D3 hanno mostrato un tasso di assorbimento bifasico nelle 
concentrazioni ematiche. Tali risultati potrebbero essere utilizzati come dati fondamentali per lo 
sviluppo di nuove terapie per condizioni ginecologiche, come ad esempio le vampate di calore. 
Un altro problema diffuso è l'utilizzo anormale di farmaci antinfiammatori non steroidei al fine di 
ridurre il dolore che porta però ad un alto rischio di sviluppare danni gastrici ed enterici. Questi pazienti 
di solito ricevono un trattamento anti-acido, ma una serie di studi clinici ha fornito prove dell'inefficacia 
degli inibitori di pompa protonica. La vitamina D, d'altra parte, sembra avere un alto potenziale 
preventivo e terapeutico. Recentemente, è stato introdotto un prodotto commerciale che, oltre alle 
proprietà anti-acide degli alginati, afferma di possedere proprietà gastroprotettive derivanti dalla 
vitamina D3 e dagli estratti vegetali. In questa ricerca, l'efficacia della vitamina D3 combinata con gli 
alginati è stata studiata analizzando la vitalità cellulare, la produzione di specie reattive dell’ossigeno 
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insieme a percorsi apoptotici e di sopravvivenza per prevenire il danno indotto da Diclofenac in cellule 
gastriche in condizioni di acidità o iperacidità.  
Analizzando gli effetti anche sul tessuto cardiaco, lo studio dimostra che la vitamina D3 ha un effetto 
cooperativo con Q10 e L-arginina su cellule cardiache (cellule H9c2) ed endoteliali (cellule PAE) per 
prevenire il danno in condizioni ischemiche. In particolare, sono stati studiati gli effetti di vitamina D3, 
Q10 e L-arginina da soli e combinati sulla vitalità cellulare, sull'ossido nitrico e sulla produzione di 
specie reattive dell'ossigeno in cellule endoteliali e cardiache. Inoltre, sono stati studiati anche il 
coinvolgimento dei percorsi PI3K/Akt ed ERK/MAPK che portano all'attivazione di eNOS ed il 
coinvolgimento del recettore della vitamina D. Gli stessi agenti sono stati testati in un modello animale 
per verificare la produzione di specie reattive dell’ossigeno e di ossido nitrico. I dati ottenuti dimostrano 
per la prima volta l'effetto benefico e cooperativo della stimolazione con vitamina D3, Q10 e L-arginina. 
In effetti, nelle cellule cardiache ed endoteliali, vitamina D3, Q10 e L-arginina combinati sono stati in 
grado di indurre una produzione di ossido nitrico superiore a quella indotta dalle 3 sostanze 
singolarmente. Gli effetti sulla vasodilatazione indotti dalla stimolazione cooperativa sono stati 
confermati anche in un modello in vivo. L'uso della combinazione di vitamina D3, Q10 e L-arginina 
potrebbe essere un potenziale metodo per ridurre le lesioni del miocardio o gli effetti 
dell'invecchiamento sul cuore. 
Per quanto riguarda la parte dello studio incentrato sulla vitamina D3 nell'invecchiamento cerebrale, è 
stata studiata la capacità della vitamina D3 combinata con l'acido lipoico di prevenire o riparare i danni 
causati dallo stress ossidativo e dall'accumulo di ferro, due diversi aspetti biologici coinvolti 
nell'invecchiamento cerebrale e nella neurodegenerazione astrocitaria. Sono state studiate la vitalità 
cellulare, il potenziale di membrana mitocondriale ed i pathways molecolari attivati in condizioni di 
stress ossidativo. Inoltre, il ferro catalitico è stato utilizzato per valutare la protezione esercitata dalla 
combinazione di vitamina D3 ed acido lipoico nella neurodegenerazione indotta. In questi esperimenti, 
sono stati studiati la vitalità cellulare, la produzione di ROS, la concentrazione di ferro e l'attivazione 
di pathways intracellulari. In questo studio, la combinazione di vitamina D3 e acido lipoico ha mostrato 
effetti benefici sulla vitalità degli astrociti. Inoltre, la vitamina D3 e l'acido lipoico sono stati in grado 
di attenuare l'apoptosi indotta da H2O2 attraverso la via mediata dai mitocondri. La combinazione è stata 
anche in grado di contrastare gli effetti negativi causati dal ferro, impedendone l'accumulo. Tutti questi 
dati supportano l'ipotesi di un'attività cooperativa esercitata dalla vitamina D3 e dall'acido lipoico negli 
astrociti, indicando una possibile nuova strategia per rallentare l'invecchiamento cerebrale. Pertanto, la 
capacità della vitamina D3 e dell'acido lipoico di contrastare l'invecchiamento cerebrale ha portato alla 
creazione di un prodotto commerciale, Cebral®. 
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1. Introduction 
Vitamin D refers to a group of fat-soluble corticosteroids hormone responsible for enhancing 
intestinal absorption of calcium, iron, magnesium, phosphate and zinc. In humans, the most 
important compounds in this group are vitamin D3 (also known as cholecalciferol) and vitamin 
D2 (ergocalciferol) [1]. 
They are presents naturally in very few foods, for example in fish (vitamin D3) and in some 
plants (mainly vitamin D2) and for this reason a number of foods have been fortified by the 
food industries. 
Vitamin D3 and vitamin D2 are inactive in many biological systems and have to undergo a 
series of metabolic transformations before exerting effects in target tissues [2-4]. Vitamin D is 
also popularly known as “sunshine vitamin” because in the skin sun exposure produces vitamin 
D. Indeed, the prohormone vitamin D3 is produced in the skin through ultraviolet irradiation 
of 7-dehydrocholesterol, than to make it biologically active the prohormone vitamin D is 
transported in the blood by the vitamin D binding protein (DBP) to the liver, where it is 
metabolized to 25-hydroxyvitamin [5]. Vitamin D is hydroxylated at C-25 by cytochrome P450 
vitamin D 25-hydroxylases in the liver, forming 25-hydroxyvitamin D (25(OH)D3). This is the 
major circulating metabolite of vitamin D in plasma, and its measurements are used to provide 
an index of vitamin D nutritional status [3, 4] 
However, 25(OH)D3 itself is metabolically inactive and must be modified before function [4]. 
On the next metabolic step, 25(OH)D3 is transported by DBP to the kidney, where in the 
proximal convoluted tubule of the nephron at the position C1 is hydroxylated, resulting in the 
hormonally active form of vitamin D 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), which is 
responsible for most of the biological actions of vitamin D [5]. As a result of 1- and 25-
hydroxylation, the prohormone vitamin D is being structurally transformed into an active 
hormone. 
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The best known target organs or tissues for 1,25(OH)2D3 are the intestine to stimulate 
absorption of calcium and phosphate and the bone to cause release of calcium and phosphate. 
Beside 1,25(OH)2D3, the kidney can also produce 24,25 dihydroxyvitamin D3 
(24,25(OH)2D3), a relatively inactive metabolite comparing to 1,25 (OH)2D3. The metabolite 
24,25 (OH)2D3 is produced by 24 hydroxyvitamin D3 24 hydroxylase from both substrates: 
25(OH)D3 and 1,25 (OH)2D3 [5, 6]. This enzyme 24(OH)D3 24 hydroxylase limits the amount 
of 1,25(OH)2D3 in target tissues by accelerating the catabolism of 1,25(OH)2D3 and by 
decreasing the amount of  25(OH)D3 available to 1 hydroxylation [5]. Vitamin D and its 
nuclear receptor (VDRs) affect the expression of many genes acting as a transcription factor 
[7] but also non‐genomic effects of vitamin D have also been described [8-15]. 
 
                                             COPYRIGHT 2007 SCIENTIFIC AMERICAN, INC 
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1.1 Seasonal Variation of Vitamin D Levels 
Seasonal variation of vitamin D is a well‐documented phenomenon [16]. The endogenous 
production of vitamin D in winter is drastically reduced because of the reduced exposure to 
UVB radiation, while in summer, exposure to UVB radiation is adequate for vitamin D 
synthesis by the skin [17].  
Studies have also shown that this seasonal variation might depend on latitude, since it has been 
found that vitamin D production is greater on latitudes close to the equator [18].  
In northern latitudes, production of vitamin D is problematic during the winter and there is an 
expected seasonal variation in vitamin D status.  
The use of sun blocking agents, that is a ubiquitous issue at all latitudes, reduced the 
endogenous vitamin D production. SPF 8 will block 95% of UVB light while SFP 15 will block 
98%, leading to decreased production of vitamin D3 from its precursor 7-dehydrocholesterol. 
Further, vitamin D is a fat soluble vitamin with a half-life of approximately 15 days [19]. 
However, vitamin D deficiency has even been reported in sunny regions [20]. This deficiency 
has been linked to many factors. For instance, skin pigmentation has a strong effect on vitamin 
D status, since it reduces the UVB radiation that effectively reaches the skin [21]. In the same 
way, sunscreen use decreases vitamin D production [22]. Another factor capable of influencing 
the metabolism of vitamin D is obesity. It has been proposed that this is due to fatty tissue 
uptake of vitamin D, reducing its bioavailability. BMI has been negatively associated with 
vitamin D levels and greater prevalence of deficiency [23-25]. Regarding age, it has been 
proposed that vitamin D deficiency in the elderly can be attributed to a decrease in the skin 
capacity to produce vitamin D due to ageing, from a lack of exposure to sunlight, or from a 
deficient dietary intake [26]. 
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1.2 Vitamin D Deficiency 
A surprisingly high prevalence of vitamin D insufficiency has been recently reported world-
wide regardless of their insolation rate [27-30]. In Canada, 30–50 % of children and adults are 
vitamin D deficient and need vitamin D supplementation [31]. Similar data have been reported 
in Australia, Brazil, Middle East, Mongolia, Africa and New Zealand documenting a high risk 
for vitamin D deficiency in adults and children [31-33]. Cross‐sectional studies of vitamin D 
status in adolescents have found deficiency in 17–47% with an increased risk in black and 
Hispanic teenagers [31-33].  
Vitamin D insufficiency is defined as levels <30 ng/ml (80 nmol/L), whereas levels below 20 
ng/ml (50 nmol/L) and 10 ng/mL (25 nmol/L) represent deficiency and severe deficiency, 
respectively (Table 1) [34]. Levels between 40 and 60 ng/mL are the preferred range, while 
vitamin D intoxication usually does not occur until 25(OH)D3 reaches levels higher that 150 
ng/ml [31]. 
 
Table 1: Blood levels of vitamin D. 
 
1.3 The Genomic Mechanism of Action of Vitamin D 
All genomic actions of vitamin D are mediated by VDR. VDR is a transcription factor and a 
member of the steroid hormone nuclear receptor family, related to the retinoic acid receptors 
and as most of the receptors has a DNA-binding domain (C-Domain), a ligand-binding domain 
(E-domain) and finally activating domain (F-domain) [2]. It has been proved that a single 
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receptor mediates all of the functions of vitamin D. This receptor is a 427 amino acid peptide 
and acts through vitamin D-responsive elements (VDREs), a complexes required for its 
genomic activity which are placed on the start site of the target gene [2]. These complexes can 
be both gene and cell specific, cells research enabling the selectivity of vitamin D3 action from 
cell type to cell type [4]. VDR was proved to be found in almost all tissues and cells. It has 
been established that the diverse biological actions of 1,25-dihydroxyvitamin D3 are initiated 
through precise changes in gene expression, which are mediated by an intracellular VDR. 
Activation of the VDR through direct interaction with 1,25(OH)2D3 prompts the receptor’s 
rapid binding to regulatory regions of target genes, where it acts to nucleate the formation of 
large protein complexes whose functional activities are essential for directed changes in 
transcription. When VDR interacts with the ligand, the repressor is no longer able to bind the 
receptor and the receptor changes conformation, forming heterodimer at the VDREs [2, 35]. 
At the same time, it binds several other proteins required in the transcription complex and 
acquires an activator [2, 35]. Once the complex is formed, DNA bends, biochemical processes 
take place, and transcription is either initiated or suppressed depending on the gene [2, 35, 36]. 
These responses are tissue-specific and range from highly complex actions essential for 
homeostatic control of mineral metabolism to focal actions that control the growth, 
differentiation and functional activity of numerous cell types including those of the immune 
system, skin, the pancreas, and bone. 
 
1.4 The Nongenomic Mechanism 
Vitamin D3 is also able to activate very rapid nongenomic mechanisms [4], lasting from 
seconds to 10 minutes [37]. This mechanism involves signal transduction pathways including 
activation of adenylyl cyclase-cAMP-protein kinase A and phospholipase C-diacylglycerol-
inositol (1,4,5)-trisphosphate-protein kinase C signal transduction pathways [38]. Particularly, 
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the second messengers Raf (rapidly accelerated fibrosarcoma)/MAPK play an important role 
because they may engage in cross-talk with the nucleus to modulate gene expression [37]. This 
firstly identified nongenomic activation is associated with the rapid stimulation of intestinal 
calcium transport called “transcaltachia” [39]. Successively, this effect was identified in the 
chondrocytes of the bone growth plate [39] and in keratinocytes of the skin [40]. Identification 
of the receptor for vitamin D3 has focused on the VDR itself albeit in a different configuration 
to identify agonists able to induce nongenomic effects [41]. Interaction between vitamin D3 
and membrane-associated rapid response steroid binding protein (MARRS) has been studied 
as well. These receptors are located in the membrane within caveolae/lipid rafts [42] where 
they are poised to activate kinases, phosphatases, and ion channels.  
 
1.5 Physiological Effects of Vitamin D  
Vitamin D is involved in mineral metabolism, bone growth and it also stimulates absorption of 
phosphate and magnesium ions; indeed, its main effect is to facilitate intestinal absorption of 
calcium. In cases when there is a lack of vitamin D, dietary calcium is not absorbed efficiently. 
The best studied of these calcium transporters is calbindin, an intracellular protein that carries 
calcium across the intestinal epithelial cell [43].  
There is evidence in the literature on the effects of vitamin D on bone tissue: it induces the 
expression of osteocalcin and suppresses synthesis of type I collagen and in cell cultures, 
vitamin D stimulates differentiation of osteoclasts. The crucial effect of vitamin D on bone is 
to provide the proper balance of calcium and phosphorus to support mineralization [43]. 
Some experiments, using cultured cells, have demonstrated that vitamin D has potent effects 
on the growth and differentiation of many types of cells. These findings suggest that vitamin 
D has physiologic effects much broader than that of a role in mineral homeostasis and bone 
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function. This is an active area of research and a much better understanding of this area will 
likely be available in the near future [43]. 
Of interest, VDRs are not only present in different tissues, such as bone, skin, intestine and 
kidneys, but also non-classical organs like brain, eyes, heart, pancreatic islets (β-cells), immune 
cells, muscle, adipose tissue, thyroid, parathyroid and adrenal glands [44].  
                       COPYRIGHT  Current Opinion in Pharmacology. Vitamin D: modulator of the immune system. 2010,10:482–496 
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Importantly, many of these non-classical tissues also express vitamin D-activating enzymes, 
hence, allowing these non-classical actions to occur via local activation of vitamin D. 
Recently, a crucial role for vitamin D also in digestive system health has been described [45].  
Vitamin D links to several target tissues in the digestive system, in the oral region, in the 
salivary glands, in the stomach and in the small and large intestine [46]. 
In gastric mucosa, vitamin D appears to have high preventive and therapeutic potentials [47] 
and it is able to regulate endocrine and paracrine secretion of gastrin with secondary effects, 
for instance, on parietal cell HCl and pepsinogen secreting chief cells [46].  
A growing body of data suggests that both vitamin D and VDR, play an important role also in 
the regulation of cardiovascular homeostasis and suggest a protective effect for vitamin D 
against cardiovascular disease [48-51]. Vitamin D3 deficiency is significantly associated with 
cardiomyopathy and increased risk of cardiovascular disease with consequent mortality [4].  
The Intermountain Heart Collaborative Study revealed that vitamin D3 blood levels below 15 
ng/mL compared to vitamin D3 above 30 ng/mL are associated with significant increases in 
the prevalence of type 2 diabetes mellitus, hypertension, hyperlipidemia and peripheral 
vascular disease, coronary artery disease, myocardial infarction, heart failure, and stroke, as 
well as with incident death, heart failure, coronary artery disease/myocardial infarction and 
stroke [51]. The ability of this hormonal system to inhibit the renin-angiotensin system [52], 
control blood pressure, inhibit cellular proliferation and hypertrophy, reduce fibrosis and 
suppress immune function suggests a variety of plausible mechanisms that could contribute to 
these palliative effects. However, the cardioprotective “hypothesis” has not been without 
controversy and results to date have been inconclusive.  
Some, but not all, observational studies in humans provide support for these experimental 
findings, raising the possibility that vitamin D or its analogs might prove useful therapeutically 
in the prevention or treatment of cardiovascular disease. For example, VDR knockout mice 
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have elevated circulating levels of renin and angiotensin II and develop hypertension [52]. A 
similar phenotype occurs in mice lacking the 1α-hydroxylase gene [53]. In mice, injection of 
1,25(OH)2D3 analogs suppresses renin production in vivo and negatively regulates the 
expression of the angiotensinogen gene [54-56].  
Vitamin D is also important in brain homeostasis; the role of vitamin D in the brain 
development and function of neurons was suggested when the first evidence of 1α-hydroxylase, 
an enzyme responsible of an active form of vitamin D and VDR, were found to be present in 
the brain [57]. The specific mechanisms that mediate the neuroprotective effect of vitamin D 
are still unclear; however, vitamin D may act in many pathways including antioxidant 
pathways, neuronal calcium regulation, immunomodulation and glutamatergic systems [58-
61]. 
A meta-analysis examining the association between vitamin D3 status and the risk of 
cerebrovascular events, including more than 1200 stroke cases, found that the pooled relative 
risk for stroke was 52% higher when comparing 25(OH)D levels ≤12.4 ng/mL with 25(OH)D 
levels >18.8 ng/mL [62]. As concerned to cerebral effects, the observed widespread distribution 
of 1α-hydroxylase and the nuclear VDR in both neurons and glial cells suggest that vitamin D3 
may have autocrine and paracrine properties in the brain [63, 64]. VDR is highly expressed in 
multiple brain regions [65] in animal [66] and human [67] brain, particularly in the pontine-
midbrain area, cerebellum, thalamus, hypothalamus, basal ganglia, hippocampus, olfactory 
system, and the temporal, orbital and cingulate areas of brain cortex [68]. Mounting evidence 
indicates that vitamin D3 and its receptors play an important role in the brain, ranging from 
neuroprotection to immunomodulation [69], cells proliferation and differentiation [70], and 
plays an important role both in developing [71] and adult brain [65]. Vitamin D3 can exert 
these effects since it is able to cross the blood-brain barrier and can bind to VDR within the 
brain [72, 73].  
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Moreover, vitamin D3 protects neurons against NMDA, glutamate, 6-hydroxydopamine and 
reactive oxygen species [74, 75]. It has been hypothesized that vitamin D3 exerts its 
neuroprotective effects via the modulation of neuronal Ca2+ homeostasis, in particular through 
the downregulation of the L-type voltage-sensitive Ca2+ channel in hippocampal neurons 
against excitotoxic insults [65], accompanied by an increase in VDR density. Vitamin D3 is 
able to inhibit proinflammatory cytokine and NOS [76] typically increased during various 
insults or disorders, such as ischemia and reperfusion, Alzheimer’s disease, Parkinson’s 
disease, multiple sclerosis and experimental autoimmune encephalomyelitis. Early vitamin D3 
deficiency may be considered as a risk factor for a number of neurological disorders including 
schizophrenia, autism [73, 77], multiple sclerosis, Parkinson’s disease and stroke [62, 78]. 
Vitamin D3 deficiency is associated with reduced cognitive function, which is an important 
issue for stroke patients [79]. Moreover, in the rat model of stroke, vitamin D3 supplementation 
has been found to reduce brain damage [80] and consequent seizures [62] and oxidative stress 
[14]. For this reason, it should be very important to study the role of vitamin D3 in 
counteracting negative effects of oxidative stress in vitro brain. So, vitamin D3 may be 
considered as a potential drug for the treatment of neurodegenerative disorders. 
 
1.6 Vitamin D specific actions on Ovarian Tissue  
In recent years, scientists have increased interest in the study of vitamin D thanks to the 
discovery of the presence of its receptor VDR in many tissues. It has been demonstrated that 
in ovarian tissues a high density of VDR is present as well [81, 82]. In female reproduction, 
the importance of vitamin D was initially appreciated in vivo, as mice who were either deficient 
in vitamin D or lacked the vitamin D receptor (VDR), suffered from underdeveloped uterus 
and an inability to form normal mature oocytes, which in turn lead to infertility [83]. In humans, 
VDR is expressed in many female organs, including the ovaries (particularly granulosa cells), 
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uterus (endometrium and myometrium), and placenta [84]. These receptors are targeted by the 
active form of vitamin D and produce an array of effects in female reproduction. For example, 
vitamin D3 regulates genes involved in estrogen synthesis [84] and it also controls several 
genes involved in embryo implantation [85]. 
 
1.6.1 Vitamin D3 and Resveratrol 
In this part of research (Project 1), the effects of vitamin D3 (vitD) and resveratrol (RES) were 
tested in ovarian cell culture and tissue. Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a 
natural antioxidant polyphenolic compound belonging to stilbene phytoalexins, a subgroup of 
non-flavonoid phenolic compounds [86, 87]. RES is contained in various vegetables such as 
berries, grapes, peanuts, besides red wine [88]. Particularly, red wine is the main source of 
RES, but a recent study discovered that peanut sprouts contain abundant RES both in cis and 
trans isoforms [89, 90]. Cis- and trans-isomers of RES coexist in plants and in wine. RES is 
rapidly metabolized in vivo and has a low water solubility, which reduces the rate-absorption 
in cells [91] reducing oral bioavailability [92]. The effectiveness of orally administered RES 
depends on its absorption, metabolism and tissue distribution. At intestinal level, RES is 
absorbed by passive diffusion or through the formation of complexes with membrane 
transporters, whereas in the bloodstream it can be found as glucuronide, sulfate, or free as well 
[93]. In some studies performed on animal models, the peak concentrations of trans-RES occur 
in blood and serum very rapidly, about 15 min from the beginning of the administration [94]. 
In different studies, RES solubility has been increased by the use of ethanol (50mg/mL) or 
other organic solvents [94]. Moreover, researchers have recently attempted to improve RES 
chemical stability, water dispersibility, bioavailability, permeability through blood–brain 
barrier (BBB) and therapeutic efficacy by using nanostructure-based drug delivery systems 
[95-97]. Epidemiologic studies have shown that RES has beneficial effects in preventing 
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various pathologic conditions ranging from cardiovascular diseases to cancer [98]. As reported 
by in vitro studies, RES can inhibit cell proliferation, induce apoptosis and block cell cycle 
progression in numerous types of human cancer cell lines, such as those of the colon, skin, 
breast, lung, prostate and liver, as well as pancreas [99]. In addition, in a few in vivo 
experimental models of colon and esophagus cancers the effectiveness of oral doses of RES 
was shown [100, 101]. RES acts as a phytoestrogen modulating estrogen receptor (ER)-
mediated transcription [102]. There is a variety of RES-sensitive tissues that are ER positive 
and the two ER subtypes in mammals, ERα and ERβ, exhibit different tissue-specific 
expression profiles [103]. Specifically, effects of RES on ER include anti-inflammatory effects 
such as protection from trauma hemorrhage-induced injury and suppression of Interleukin-6 
expression in the liver, intestine and cardiovascular system [104]. However, RES does not 
induce proliferation of mammary or uterine tissues, allowing it to be taken as a dietary 
supplement. RES binds and increases the transcriptional activity of estrogen receptors (ERα 
and ERβ) at 50–100 μM [103, 104-106]. RES displays a great affinity for ER behaving as either 
agonist or antagonist in a cell- and tissue specific manner [107]. This is important to explain 
the effectiveness of RES in reducing the number of vasomotor episodes and the intensity of hot 
flashes (HF), with the transition from moderate/severe to mild symptoms in 78.6% of patients 
[108]. The common incidence of hot flashes is around 75% and presently hormone replacement 
therapy is the gold standard in the management of moderate to severe vasomotor symptoms 
associated with menopause. RES has also been associated with anti-inflammatory effects, 
particularly in tissues that contain a large number of estrogen receptors, through this connection 
has been studied, but there are few studies on the mechanisms activated [109, 110].  
It has been demonstrated that in ovarian tissues a high density of VDR is present as well [81,  
82] and vitD acts through intracellular mechanisms similar to what observed for RES [111]. 
The role of vitD in cellular growth regulation is demonstrated by its ability to arrest cells in the 
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G1/G0 phase of the cell cycle, and by up-regulating p21, a powerful tumor suppressor gene. 
Thus, vitD can control cell division and proliferation [112]. VitD also has important anti-
proliferative, anti-angiogenic and pro-differentiative effects in a wide range of cancers [113]. 
Many of the bioeffects of RES overlap with reported benefits from high circulating levels of 
vitD. Thus, given the ability of vitD to elicit a wide range of bio-effects via transcriptional 
regulation, it is interesting study RES in the context of VDR signaling to help in elucidating 
the molecular pathways involved by these two dietary lipophilic substances in optimizing 
healthspan and well aging [112]. The potential for RES to modulate vitamin D receptor 
signaling has recently been postulated [114, 115]. There is an overall structural symmetry and 
parallel configuration of RES and known VDR ligands, which could suggest that RES might 
serve as a low-affinity VDR ligand with the ability to activate VDR. Intriguingly, several 
targets emerge such as eNOS, cyclooxygenase and Akt kinase, all of which are likewise 
regulated by vitD [116]. Finally, vitD exerts beneficial effects on ovarian tissues preventing 
ROS-derived cellular injury [82]. Therefore, since these two substances have similar effects on 
ovarian cells, some form of interaction in exerting effects can be hypothesized. This could lead 
to interesting results for future clinical use in menopause-related conditions like hot flashes.  
 
1.7 Vitamin D and Gastric Disorders 
Recently, a crucial role for vitamin D in digestive system health has been described [45]. In 
gastric mucosa, vitamin D appears to have high preventive and therapeutic potentials [47] and 
is able to regulate endocrine and paracrine secretion of gastrin with secondary effects, for 
instance, on parietal cell HCl and pepsinogen secreting chief cells [46]. A problem related to 
the gastric system is the disproportionate use of nonsteroidal anti-inflammatory drugs 
(NSAID); indeed, around 30 million people consume NSAID to manage pain, inflammation 
and fever [117, 118]. The action mechanism of these drugs consists in the inhibition of the 
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biosynthesis of prostaglandins, the inactivation of cyclooxygenase and an increase in 
leukotrienes production [119], but adverse events, such as alterations in renal function, effects 
on blood pressure, hepatic injury and platelet inhibition, are a challenge in clinical treatment 
optimization [120]. However, severe gastrointestinal disorder accompanied by gastric mucosal 
perforation and bleeding is a major concern as well as the worst outcome of prolonged NSAID-
therapy [121]: indeed, they induce gastric mucosal lesions because of their acidic properties 
[119]. The mechanism behind gastric damage involves a highly acidic gastric environment that 
favours the migration of nonionized lipophilic NSAID into the epithelial cells and at the cell 
surface these are dissociated into ions, trapping hydrogen ions and inducing mucosal injury. 
This action is further enhanced by the decrease mucosal blood flow, secretion of mucous and 
bicarbonates, and the defensive factors of the gastric layer [119]. Indeed, these side effects lead 
to reduced intestinal mucus formation, disturbed micro-circulation causing increased intestinal 
motility and increased mucosal permeability to many inflammatory mediators including 
neutrophils and cytokines [122]. The consequences can range from dyspepsia to severe peptic 
ulcer and bleeding; endoscopically the range from subepithelial haemorrhages and erosions to 
total destruction of epithelial membrane and full thickness ulcer [123]. Diclofenac, an 
anthranilic acid derivative with pKa of 4.0 [117], is the most widely prescribed NSAID for 
treating several forms of pain and inflammation [124-126]. The main clinical problem of 
Diclofenac is toxicity induced by oxidative tissue injury in the intra-mitochondrial 
environment, which appears to play a prominent role in the pathophysiology of digestive 
ulceration [117, 127, 128]. For these reasons, NSAID users are subjected, often empirically by 
doctors, to anti-acid treatments such as the proton-pump inhibitors (PPI) [129], thus, not 
surprisingly, NSAID and PPI are among the most frequently co-prescribed drugs worldwide 
[130]. Moreover, a number of clinical studies have provided the support for the ineffectiveness 
of PPI in preventing or reducing the NSAID-damages [131-133]. Indeed, current evidence 
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suggests that PPI are also associated with numerous side effects such as hypergastrinemia 
[134], enteric infections [135], adverse cardiovascular events [136] and increased mortality 
rates [137]. The need for NSAID clinical use despite their side effects encourages continuous 
research to create novel agents able to counteract their adverse effects with better safety profile, 
in particular using natural compounds. Recently, a product has been introduced that, in addition 
to having the antacid properties of alginates, claims to possess gastroprotective properties 
deriving from vitamin D3 and from plant extracts. It has been tested alone and combined with 
Diclofenac in order to provide an effective and safer strategy for the management of NSAID-
induced gastroenteric lesions (Project 2).  
 
1.7.1 Vitamin D and Alginates 
There is a new group of widely used molecules that includes alginates, a polymer of alginic 
acid derived from the cell wall of various brown algae [138]. Alginates are polysaccharides 
composed of two β-d-mannuronic acid (M) and α-1-glucuronic acid (G) monomers which are 
held together by β 1,4 bonds [139, 140]. Recently, there is a growing interest in alginates as a 
therapy for Gastro-Esophageal Reflux Disease (GERD) [141]. Alginates are able to block the 
HCl reflux in a mechanic manner; indeed, they do not have any pharmacologic property [142]. 
The mechanism of action of alginates has been called “rafting”, which means that in the 
presence of gastric acid, they form a gel in which carbon dioxide (resulting from the splitting 
of bicarbonate) is trapped. Then the gel is carried to the top of the gastric contents neutralizing 
the acidity and preventing the ascent of acid material into the esophagus [143]. The advantage 
of alginate-based reflux suppressants over antacid alone is that they provide rapid and longer-
lasting symptom relief [144]. 
It was seen that it is useful to associate alginates with natural substances. This association has 
been found to be effective in promoting stomach health, reducing inflammation and supporting 
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the immune system. Moreover, alginate/antacid system has been used as a carrier of probiotic, 
drugs and plant extracts [145]. For example, alginate/bicarbonate combined with two herbal 
gastroprotective extracts (Opuntia ficus-indica and Olea europaea) has been successfully 
evaluated in patients with GERD [145].  
Recent studies have explored a possible role of vitD on gastroprotection [45, 146]. VitD binds 
its receptor VDR which is present in several tissue targets in the digestive system, in particular 
in the oral region and in epithelial cells of the oral cavity, tongue and gums. In addition, vitD 
appears to have a therapeutic role in gastric mucosa as well, stimulating cell proliferation and 
differentiation [147] and regulating endocrine/paracrine gastrin and pepsinogen secretions 
[148]. Finally, vitD acts on smooth muscle cells in the pyloric region and in different areas of 
the small intestine [148]. Furthermore, the low plasmatic level of vitD is found to be 
responsible for an insufficient emptying of the stomach, swelling, constipation and intestinal 
irritation [148]. After the binding between vitD and its receptor, several intracellular events 
involved in different mechanism start, including the protective role against oxidative stress 
[149], the regulation of autophagic pathways through the regulation of ATG16L1, a protein 
complex necessary for autophagy [35], and the ability to inhibit apoptosis by increasing the 
expression of endothelial nitric oxide synthase (eNOS) leading to the nitric oxide (NO) 
production [149]. In this context, vitD can exert some beneficial effects on gastric tissue. For 
this reason, its use in association with other gastroprotective agents such as alginates can 
increase therapeutic efficacy of the formulation in respect to the efficacy that would be obtained 
only with gastroprotective drugs. 
 
1.8 Vitamin D and Cardiovascular System 
VitD is also a modulator of vascular wall growth as well [150] and induces a decrease in the 
expression and/or secretion of proinfammatory and proatherosclerotic factors in the 
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endothelium [151]. The role of endothelium as a target of vitD is demonstrated by the study 
published by Zehnder et al. [152], in which the expression of mRNA and protein for lα-
hydroxylase in human endothelium was shown for the first time. These findings demonstrated 
the direct effects of vitD on endothelial function, whose alteration plays an important role in 
the development of atherosclerosis. Indeed, vascular endothelial function is a crucial element 
as regards cardiovascular function and its impairment is an early manifestation of 
atherothrombotic disease [153, 154]. Endothelium acts as a barrier and a regulator of blood 
vessel activity [154] mainly through NO, which can stimulate the relaxation of the underlying 
smooth muscle, leading to vasodilation [154]. NO is produced by vascular endothelial cells in 
response to different stimuli and acts as a messenger molecule [154], activating guanylate 
cyclase to enhance cGMP, which in turn causes relaxation of smooth muscle and vasodilation 
[155]. NO is produced by nitric oxide synthases (NOS) which utilize L-arginine as their 
principal substrate, oxidizing it into L-citrulline and NO [153, 156]. The endothelial isoform 
of NOS (eNOS) is constitutively expressed in endothelial cells and is responsible for the basal 
release of nitric oxide from the endothelium and for the rapid change into nitric oxide flux in 
response to physical stimuli and molecular agonists [153, 157]. A decrease in endothelial NO 
production appears in the early phases of atherosclerosis development [158, 159]. Moreover, 
NO synthesis impairment is involved in a number of cardiovascular diseases such as peripheral 
vascular disease, congestive heart failure and cerebrovascular events [154, 160, 161]. The 
impaired NO status may cause an overproduction of reactive oxygen species in the vasculature, 
representing a risk factor for cardiovascular disease.  
 
1.8.1 Vitamin D and Protective Molecules 
Numerous studies have shown that acute and chronic supplementation with L-arginine 
improves NO production by endothelium in individuals with risk factors for atherothrombosis, 
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as well as in individuals with established atherothrombotic disease [153]. For this reason, 
extracellular L-arginine concentration is the principal determinant of intracellular L-arginine 
availability for eNOS [153]. Another important element to maintain ROS production at basal 
level is the use of “natural” substances able to modulate metabolic pathways and to treat 
pathological conditions. Many studies suggest that a number of natural compounds such as 
coenzyme Q10, vitD and other products, included in the nutraceuticals group, have the potential 
to target multiple pathways under these pathological conditions [162-164]. For example, with 
regard to cardiovascular diseases, there is strong evidence that demonstrate the link between 
oxidative stress and impaired mitochondrial function [165, 166]. CoQ10 is located in the 
mitochondria, lysosomes, Golgi apparatus and plasma membranes and provides an antioxidant 
action either by direct reaction with free radicals or by regeneration of tocopherol and ascorbate 
from their oxidised state [167, 168]. Endogenous synthesis of CoQ10 in the body decreases 
with age. It has been observed that up to 75% of ischemic heart disease patients exhibit low 
levels of CoQ10 in the plasma and in the heart in relation to the course of the disease [169, 
170]. A long-term therapy with CoQ10 has been shown to decrease heart failure symptoms, to 
reduce major adverse cardiovascular events and mortality and to be safe and well tolerated 
[171]. CoQ10 has been reported to have many biological effects both in vitro and in vivo [172, 
173]. CoQ10 is commonly used for prevention and treatment of many cardiovascular diseases 
such as myocardial infarction, congestive heart failure and other drug-induced or disease-
induced cardiomyopathies [168, 174, 175]. Moreover, Q10 showed the ability to prevent 
oxidative stress, apoptotic cell death and monocytes cell adhesion in HUVEC [176]. On the 
basis of the results obtained in this research field, it is possible to speculate on the possibility 
of preparing a mixture of antioxidants and vitamins able to prevent cardiovascular diseases. 
Some studies demonstrate that a mix of micronutrients, including vitD, significantly reduces 
markers of lipid peroxidation and at the same time increases antioxidant potential of the 
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molecules contained. The importance of vitamin D in the cardiovascular system is evidenced 
by the observation that the deletion of VDR from the heart results in hypertrophy [177, 178] 
and contributes to the acceleration of atherosclerosis [4, 179]. Both experimental and clinical 
studies support the protective role of vitamin D in vascular system and in cardiac function 
through lowering blood pressure, improving endothelial function, inhibiting oxidative stress 
and reducing the activity of renin-angiotensin system [180]. Additional studies demonstrate the 
possible autocrine/intracrine mechanisms exerted by vitamin D as a modulator of endothelial 
functions [181]. In addition it has been demonstrated that the control on NO production exerted 
by vitD is mediated by VDR and related to intracellular pathways leading to eNOS activation 
[181]. Therefore, the VDR modulation could represent a new treatment option for all 
cardiovascular diseases in the future [182]. 
Thus, in the present study (Project 3) it was examined the effects of combination of vitD, Q10 
and L-arginine on cell viability and NO/ROS production in endothelial and cardiac cells in 
order to assess a potential cooperative effect of these substances on cardiovascular function at 
the cellular level. 
 
1.9 Vitamin D in Nervous System 
The effects of vitamin D also affect the central and peripheral nervous system. Vitamin D 
receptors are in fact present throughout the brain including the primary motor cortex, the region 
that coordinates movement [183-185]. Specifically, VDRs have been identifIed in neuronal 
and glial cells in several brain areas including the cortex, deep gray matter, cerebellum, 
brainstem nuclei, spinal cord and the ventricular system [185.]. Furthermore, the enzyme 1α‐
hydroxylase, the activator of vitamin D precursors, is also present in the brain [183-187]. 
Vitamin D levels are associated with the conductance velocity of motor neurons and 
neurotransmission mediated by dopamine, serotonin, acetylcholine, GABA and the 
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catecholamines [186, 187]. The combination of in vitro, ex vivo and animal model data provides 
evidence that vitD has a crucial role in neuronal proliferation, differentiation, 
neurotransmission, neuroplasticity and neuroprotection and its levels correlating to the levels 
of several neurotrophic factors including nerve growth factors (NGF) and that of neurotrophins, 
which play crucial roles in the maintenance and growth of neurons [188, 189].  
Some evidence implicates vitD as a candidate in influencing susceptibility to a number of 
psychiatric and neurological diseases, such as schizophrenia, autism, Parkinson disease (PD), 
amyotrophic lateral sclerosis, epilepsy, Alzheimer disease (AD) and is especially strong for 
multiple sclerosis (MS) [190-192]. 
The neuroprotective effect of vitD has been recently reported in cognitive decline of aging rats 
[193], and it has been extensively studied in the animal model of MS and the experimental 
allergic encephalomyelitis. The hormone prevents onset and reversibly blocks progression of 
clinical signs, but such a protective effect is absent in VDR knockout mice [191]. The effect of 
vitD might not be due exclusively to its neuro-immunomodulatory properties [191] since 
recently it has been reported that the hormone enhances neural stem cell proliferation and 
differentiation into neurons and oligodendrocytes, the myelinating cells of central nervous 
system [194, 195]. Neural stem cells constitutively express VDR, which can be upregulated by 
vitD [194]. VitD regulates the expression of many AD-related genes. It attenuates Aβ peptide 
accumulation by stimulating phagocytosis of Aβ peptide probably by modulating transcription 
of Toll-like receptors and cytokines together with enhancing brain-to-blood efflux transport by 
increasing P-glycoprotein expression [196]. Alterations in adult neurogenesis appear to be a 
common hallmark in different neurodegenerative diseases including PD and AD [197]. 
Therefore, factors that stimulate neurogenesis have been indicated as possible treatments of 
neurodegenerative disorders.  
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Moreover, the combination of anti-neurodegenerative drugs with vitD supplementation might 
be useful. Indeed, the supplementation of the combination nemantidine plus vitD has been 
shown to prevent cognitive decline more efficiently than that of the single compounds [198]. 
In addition, vitamin D exerts direct neuroprotective effects via the synthesis of proteins binding 
calcium (Ca2+) ions; it is important in neuronal function and in neuronal transmission. Proper 
levels of neuronal calcium are critical because their excess may result in the formation of ROS 
with consequent neuronal damage. Indeed, vitamin D levels are inversely associated with 
oxidative stress which damages the brain leading to neuronal apoptosis or necrosis [199]. 
Vitamin D also affects neuroplasticity, a process in which neural synapses and pathways are 
adapted to the needs of environmental and behavioral demands adjusting the brain to noxious 
stimuli diseases or environmental cues [185, 200, 201]. The VDRs in glial cells play in the 
uptake and release of neurotransmitters, including that of GABA neurotransmission within the 
motor cortex [202]. GABAergic function is the principal “brake” within the brain affecting 
muscle relaxation via the corticospinal neurons [203]. 
 
1.9.1 Vitamin D3 and Lipoic Acid 
Alpha-lipoic acid (LA) is a fatty acid containing 8 carbons and 2 sulfur molecules in a 
dithiolane ring [204]. Initially discovered as a bacterial growth factor in potato extract, LA was 
later isolated and characterized from bovine liver [205, 206]. It is naturally synthesized in the 
liver and other tissues and obtained from various animal and plant sources in the diet. LA is a 
potent antioxidant, acting as a cofactor for mitochondrial enzymes, pyruvate dehydrogenase, 
α-keto-glutarate dehydrogenase activity and branched chain alpha-keto acids. In addition, LA 
affects numerous inflammatory pathways by modulating the NF-κB-dependent gene 
expression [207-210]. LA’s antioxidant properties were identified in 1959 when Rosenberg 
and Culik found that the administration of LA to vitamin C-deficient guinea pigs relieved 
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scurvy symptoms [211]. LA has been used for decades in Germany to treat diabetic neuropathy, 
cirrhosis and mushroom and heavy metal poisonings [212]. Endogenous LA occurs in the R 
chiral conformation (R-LA) at the C6 carbon atom. Manufacturing LA produces racemic LA, 
an even mix of the R-LA and S-LA chiral conformations. The bioavailability and bioactivity 
of racemic vs R-LA is debated [208, 213]. The functional activity of LA derives from the 
disulfide bond between the 2 thiol groups that cycles between the oxidized (LA) and reduced 
conformations (dihydrolipoic acid, DHLA). LA is highly reactive to free radicals, preventing 
oxidative damage by directly scavenging and neutralizing ROS [204, 210]. 
Several randomized clinical trials have demonstrated that LA can act as a therapeutic agent in 
chronic diseases such as diabetes mellitus [214], cardiovascular diseases [215] and cancers 
[216] by decreasing chronic inflammation and improving glucose-insulin homeostasis and 
endothelial function [217]. It has also been shown that LA exerts beneficial effects on the redox 
state of the plasma and endothelium-dependent vasodilation [218]. Previous studies have 
demonstrated that LA can decrease lipopolysaccharide-induced inflammatory responses and 
act as an anti-inflammatory agent through affecting the cyclooxygenase-2 [219, 220] and 
inducible nitric oxide synthase (iNOS) [221]. 
LA binds to Cu and Fe preventing their production of free radicals. In mitochondria, the 
LA/DHLA redox couple serves as a key cofactor of the pyruvate dehydrogenase complex and 
α-ketoglutarate dehydrogenase of the Krebs cycle, and aids synthesis of nucleic acids, thereby 
improving mitochondrial efficiency and reducing ROS generation [210, 212]. LA modulates 
also the PKB/Akt signaling pathway important for vascular endothelial integrity and the redox-
sensitive transcription factor Nrf2 and NF-κB pathways, thereby indirectly promoting an 
antioxidant environment [222-225]. 
There is no doubt that it is a strong antioxidant, but due to certain reasons its use for medicinal 
purposes is prohibited; however, in some states it is used as a supplement and in others as a 
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remedy [226, 227]. These restrictions are due to some endogenous characteristics of substance 
by itself, such as the changeableness due to the disclosing of dithiolane ring and the emergence 
of disulfide bond between molecules. Other properties that limit the oral use of LA are its 
decreased ability to become dissolved in the gastrointestinal tract and increased rate of hepatic 
metabolism. In addition, besides it is widely known antioxidant potential, LA has also many 
other functions, as it is its involvement in mitochondria producing energy, by acting as cofactor 
for various enzymes involved in metabolism [226]. For its antioxidant effect, LA has been used 
in combination with vitD to study the capacity to prevent or repair the damage caused by 
oxidative stress and neurodegeneration (Project 4). 
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2. Aims of the Thesis 
In recent years, vitamin D has seen growing interest among researchers, especially due to the 
presence of its receptor VDR in many tissues and organs. For this reason the biological effects 
of vitamin D3 (the active form of vitamin D, 1,25-dihydroxyvitamin D3, vitD) mediated by the 
interaction with VDR were studied in different tissues (ovarian, gastric, cardiac and brain).  
➢ It has been demonstrated that in ovarian tissues a high density of VDR is present as 
well and vitD acts through intracellular mechanisms similar to what observed for 
resveratrol, a natural antioxidant polyphenol able to exert a wide range of biological 
effect on several tissues. Despite its important beneficial properties, it has a low water 
solubility, which limits its therapeutic applications in humans. The aims of this part of 
research (Project 1) were to evaluate the cooperative effects of resveratrol (RES) 
combined with vitD on ovarian cells studying cell viability, ROS production, activated 
pathways in in vitro study and in in vivo study to quantify vitD and RES, to analyze the 
concentration of radical oxygen species and to study activated pathways. Moreover, the 
modulation of specific intracellular pathways involving ER and VDR receptors has 
been studied to hypothesize a future clinical use in menopause related conditions like 
hot flashes. 
➢ Since vitD appears to have gastroprotective properties, the effects of vitD have been 
studied also in stomach combined with alginates (Project 2); it has been tested alone 
and combined with Diclofenac in order to provide an effective and safer strategy for 
the management of NSAID-induced gastroenteric lesions. Hence, the primary objective 
of this research was to evaluate whether it is possible to improve the protection of the 
gastric mucosa during therapy with Diclofenac. Thus, the present study was designed 
to examine the protective effects of alginates combined with vitD assessing its effects 
on factors related to gastric protection such as viability, radical productions and 
intracellular mechanism involved.  
➢ As regards the research part focused on vitD in cardiovascular system (Project 3), the 
effects of combination of vitD, Q10 and L-arginine on cell viability and NO/ROS 
production in endothelial and cardiac cells were evaluated in order to assess a potential 
cooperative effect of these substances on cardiovascular function at the cellular level. 
Moreover, the involvement of PI3K/Akt and ERK/MAPKs pathways leading to eNOS 
activation has been investigated. To confirm data, the same agents were also tested in 
an animal model to assess vasodilation, NO and ROS production. 
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➢ As regards the research part focused on effects of vitD in brain ageing (Project 4),  the 
ability of vitD combined with lipoic acid (LA) has been studied to prevent or repair the 
damage caused by oxidative stress and iron accumulation, two different biological 
aspects involved in brain ageing and neurodegeneration. Cell viability, mitochondrial 
membrane potential and pathways activated in oxidative condition has been studied. In 
addition, to investigate the protection exerted by combination of vitD and LA in 
induced neurodegeneration using catalytic iron, cell viability, ROS production, iron 
concentration and activation of intracellular pathways have been studied in order to 
hypothesize a new human anti-ageing treatment. 
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3. Materials & Methods 
3.1 Cell Culture 
In order to investigate the effects of vitD mediated by VDR receptor in different tissues, we 
used several cell types which of them some directly isolated by organ of interest. 
● Project 1 (ovarian line of research) 
CHO-K1 cells (Chinese Hamster Ovary cell), an epithelial cell line derived as a subclone from 
the parental CHO cell line initiated from a biopsy of an ovary of an adult Chinese hamster 
[228], have been purchased from Lonza (Basel) and cultured in Dulbecco’s modified Eagle’s 
medium: Nutrient Mixture F-12 (DMEM-F12; Sigma, Milan, Italy) supplemented with 10% 
fetal bovine serum (FBS, Sigma, Milan, Italy), 2mM glutamine and 1% penicillin/streptomycin 
(Sigma, Milan, Italy) and incubated at 37°C, 5% CO2, and 95% humidity [229]. When the cells 
reached 80–90% of confluence were seeded for different experiments; 1×104 and 2.5×104 cells 
were plated in a 96-well for MTT test and ELISA activation assay, respectively; 1×105 cells 
plated on 24-well plates to analyzed ROS production; for Western blot analysis and SOD 
activity the cells were seeded in 6 wells and maintained until 85% of confluence. 
● Project 2 (gastric line of research) 
Primary epithelial gastric cells were obtained from the stomach of anaesthetized prepubescent 
pigs as previously described [45]. Briefly, the gastric cells were isolated using enzymatic 
solution in agitation (collagenase/dispase solution, Sigma-Aldrich, Milan, Italy) for 60 minutes 
at 37°C, centrifuged at 1500 rpm for 5 minutes at 4°C and then the pellet resuspended in 
complete medium (Ham’s F12 supplemented with 10% FBS, Sigma-Aldrich, Milan, Italy) on 
collagen coated dishes. The cells used for the experiments were obtained from passage 3 to 
passage 5. The cells were used to perform different experiments; to study cell viability, ATP 
level and NO production 1x104 cells were plated on 96 well-plates; to study ROS production 
1x105 cells were plated on 24 well-plates; to study the intracellular pathways by Western blot 
33 
 
and to analyse the activities by kit ELISA the cells were plated on 60mm dishes until 
confluence. To synchronize the cells, before stimulations they were maintained in DMEM 
without red phenol and FBS and supplemented with 1% penicillin/streptomycin, 2mM L-
glutamine and 1mM sodium pyruvate in an incubator at 37°C, 5% CO2 and 95% humidity for 
18h and then to create a similar condition of human stomach, the cells were maintained for 2h 
on acidified medium (HCl was added at DMEM without red phenol and FBS and supplemented 
with 1% penicillin/streptomycin, 2mM L-glutamine and 1mM sodium pyruvate to obtain a 
medium with pH 4) before the stimulation. This acidified medium was maintained during the 
successive stimulations. 
● Project 3 (cardiovascular line of research) 
Experiments were performed on both PAE and H9c2 cells.  
Porcine aortic endothelial cells (PAE) were purchased from Cell Applications, Inc. (San Diego, 
CA, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, Milan, 
Italy) supplemented with 10% fetal bovine serum (FBS; Sigma), 2mM L-glutamine (Sigma), 
1% penicillin-streptomycin (Sigma) at 37°C with 5% CO2, as reported in literature [230]. The 
cells were plated to 1x104 in 96-well plates to analyze cell viability using MTT test, to evaluate 
NO production and ROS production using Griess assay and a rate of superoxide release, 
respectively. To study the intracellular pathways using Western blot, they were plated in a 6-
well until confluence (about 90%). 
Rat cardiac cells (H9c2) were obtained from the American Type Culture Collection (Rockville, 
MD) and cultured in Dulbecco modified Eagle Medium (DMEM; Sigma, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS; Sigma), 1% penicillin–streptomycin (Sigma) 
and 2mM L-glutamine (Sigma) in an incubator at 5% CO2, and 37°C, as reported in literature 
[231]. The experiments were performed with cells from passages 14–17. The cells were plated 
to 8x103 in 96-well plates to analyze cell viability using MTT test; to evaluate NO and ROS 
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production using Griess assay and a rate of superoxide release, respectively; finally, to study 
the intracellular pathways using Western blot, cells were plated in a 6-well until confluence 
(about 90%). Both cell lines before the experiments were maintained in DMEM 0% serum 
supplemented with L-glutamine, penicillin-streptomycin without red phenol (starvation 
medium) for 4-18h.    
● Project 4 (brain line of research) 
Experiments were performed using both primary mouse astrocyte and HUVEC cells.  
Primary mouse astrocyte cultures were prepared from both male and female C57BL/6 mouse 
pups, following a classical technique described elsewhere [232] according to the National 
Guideline for the Use and Care of Laboratory Animals. Briefly, within 24 h of birth, pups were 
euthanized and cortices were dissected, minced, mechanically digested, and let settle for 30 min 
at room temperature. Then the cell suspension was centrifuged at 800 rpm for 5min. Pelleted 
cells were resuspended in Neuronal Basal Medium (Sigma-Aldrich), supplemented with 5% 
fetal bovine serum (FBS, Gibco), 1% penicillin/streptomycin (Sigma-Aldrich), and 2mM L-
glutamine (Sigma-Aldrich), plated in multiwells and maintained in culture for 6 days before 
treatment. Astrocytes should be separated from microglia and oligodendrocyte precursor cells 
by shaking, as reported in literature [233]. For the experiments, 1×104 cells on a 96-well plate 
were plated to study cell viability by the MTT test, amyloid precursor protein (APP) by the 
ELISA test, and ROS production by the colorimetric test; 1×104 cells on a black 96-well plate 
to analyze the oxygen consumption by a fluorescence kit; 1×106 on a 6-well plate to determine 
the iron concentration by the colorimetric assay; 1×106 on a 6-well plate to analyze the 
intracellular pathways activated by Western blot analysis; 1×106 on a 6-well plate to analyze 
p53 activity and ERK/Akt activation; and 4×104 on Transwell support to study the 
permeability, to quantify vitD and LA. Before stimulations, the cells were maintained in 
Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) without red phenol and fetal 
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bovine serum (FBS, Sigma-Aldrich) and supplemented with 1% penicillin/streptomycin 
(Sigma-Aldrich) and 2mM L-glutamine (Sigma-Aldrich) in an incubator at 37°C, 5% CO2 and 
95% humidity for 3h. 
 
Human umbilical endothelial cells (HUVEC), cells derived from the endothelium of veins from 
the umbilical cord, were used in order to obtain a co-culture together with astrocytes as an 
experimental in vitro model of BBB. HUVEC were purchased from ATCC®. Cells were 
cultured in EGM Media (Lonza) supplemented with 10% FBS (Gibco), 1% 
penicillin/streptomycin (Sigma-Aldrich), and 2mM glutamine (Sigma-Aldrich) in an incubator 
at 37°C, 5% CO2 and 95% humidity. For the experiments, 1×10
5 HUVEC cells/cm2 were plated 
in the apical compartment of 6.5mm Transwells with a 0.4μm pore size polyester membrane 
(Corning Costar, Sigma). 
  
3.2 Animal Model 
In order to verify the effects observed in vitro, some experiments were performed also in in 
vivo studies. 
● Project 1 (ovarian line of research) 
Female Wistar rats weighing 300 to 350g (n = 94) purchased from Envigo++++ (Bresso, Italy), 
were housed in a room at a constant temperature of 25°C on a 12h/12h light/dark cycle with 
food and water available ad libitum. All experiments were conducted in accordance with local 
ethical standards and prospectively approved by the University OPBA (Organismo Preposto 
al Benessere degli Animali, Animal Wellness Committee). Experimental protocols were 
approved by national guidelines (Ministero della Salute authorization number 914/2015-PR) 
and in accordance with Guide for the Care and Use of Laboratory Animals (National Institutes 
of Health publication 86–23, 1985 revision). 
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● Project 3 (cardiovascular line of research) 
Male Wistar rats weighing 350 to 400g (n=125) were housed in a room at a constant 
temperature of 25°C on a 12-hour/12-hour light/dark cycle with food and water available ad 
libitum. All experiments were conducted in accordance with local ethical standards and 
protocols approved by national guidelines (legislative decree (DLGS), January 27, 1992, 
license 116) and in accordance with Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health publication 86-23, 1985 revision). For each animal, anesthesia 
was performed via sevoflurane (5% for induction and 3% for maintenance) in oxygen [169]. A 
heat pad maintained the temperature of the animals. Under sterile conditions, rats underwent 
surgical procedure, thoracotomy, to expose and isolate aorta in order to perform the injection 
and to measure blood flow, using flowmeter probe (model 420, Transonic Systems, Inc., Ithaca, 
NY) positioned around the vessel. Aortic blood and tissue were sampled immediately after the 
end of treatments. Heart rate and respiratory rate were also continuously monitored. Aorta was 
the better choice to study cardiac function of drugs [234]. Additional experiments were 
performed to study the effects of combination of vitD, Q10 and L-arginine and after ischemia-
reperfusion injury. Ischemia was induced following a classical technique [235], clamping 
isolated aorta downstream of the induction point. The clamp was maintained for 30min 
monitoring aortic blood flow. After that, the clamp was removed and reperfusion was 
maintained for 1h, monitoring aortic blood flow. Finally, during reperfusion, some animals 
were treated with QLD (Q10+L-arginine+ vitD) and monitored for 1h.   
 
3.3 Experimental Protocol 
Since the experiments explore the effects on different tissues, we subdivided the experimental 
protocol following this order: ovarian, gastric, cardiovascular and brain fields. 
● Project 1 (ovarian line of research) 
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CHO-K1 cells were treated with Resveratrol (RES) in a range of 10-100μM to determine an 
optimal concentration; 50μM was chosen and its efficacy verified in a time-course study (from 
2 min to 48 h). The RES concentration was chosen basing on previous studies about the 
therapeutic range of ovarian evidence [236, 237] and on the experiments of dose-response 
study. RES was prepared in lipidic solvent that was also tested alone in CHO-K1 cultures. The 
cooperative activity of RES with vitD, was also tested, evaluating the effects of the co-
stimulation with RES 50μM and vitD 100nM [238] in CHO-K1 cells during time. In addition, 
in order to study the bioavailability, 0.5mg RES were administered by gavage in Female Wistar 
rats following a standard technique [239, 240]; the quantity of RES was calculated by the 
conversion formula (animal-man) approved by FDA [241]. For each animal, anesthesia was 
performed via isoflurane (1.2–1.5 Mean Alveolar Concentration) in oxygen and gavage was 
carried out using probe-ended stainless-steel gastric tubes (80×1.5 mm, length×outer diameter). 
After treatment, rats were placed in individual cages and housed separately for the duration of 
the study and daily monitored. The animals were randomized in different groups: n = 36 treated 
with RES lipophilic formula; n = 36 with RES plus vitD 0.4μg lipophilic formula; n = 18 treated 
with vitD 0.4μg alone; n = 4 untreated (control) and sacrificed at T0. Time-point for each 
treatment (2, 5, 15, 30, 60, 180, 360, 720, 1440min) was conducted in triplicates. The animals 
were euthanized by CO2 asphyxiation at each time point and the organs (liver, stomach, 
intestine, heart, kidneys and ovaries) were withdrawn to evaluate biodistribution of the 
different RES formulations, and to evaluate the ovarian tissue integrity by Western blot. In 
addition, blood samples used for RES determination by HPLC analysis, ROS and vitD 
quantification (by ELISA kit) were collected at each time-point using CBC tubes to obtain 
plasma by centrifugation at 3000 rpm for 15min at room temperature. 
● Project 2 (gastric line of research) 
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Primary epithelial gastric cells were used to analyze the effect of Aquilea Reflux® (Aq) and 
Neobianacid® (Neo) in preventing or reverting the damage caused by anti-inflammatory drugs 
(in particular Diclofenac) during oxidative stress or hyperacidic condition. Aq and Neo were 
tested in preliminary experiments before or after 200μM H2O2 or 1:172 (%v/v) HCl to 
determine the effects (prevention or repair, respectively) during oxidative stress or gastric 
hyperacidity. The time of stimulation was 24h, in order to observe cell viability, ATP 
consumption, ROS production and intracellular pathways activations. Since the greatest effects 
were observed during hyperacidic condition, this state was maintained during successive 
stimulations with anti-inflammatory drugs. In particular the protective effects on gastric 
epithelial cells of Aq and Neo were examined during pre and post stimulations with 250μM 
Diclofenac (D). The time of stimulation was 24h to study the effects on cell viability, ROS 
production and the intracellular pathways involved. To confirm the potential use of Aq and 
Neo as gastroprotective agents, some data were compared to those obtained from experiments 
with 10 μM Pantoprazole (P), added before Diclofenac. 
● Project 3 (cardiovascular line of research) 
The study can be divided in two parts: in the former in vitro were performed whereas in the 
latter experiments were in vivo. In in vitro experiments, both PAE and H9c2 cells line were 
used to study the cooperative activity of different biological substances such as vitD, Q10 and 
L-arginine and to demonstrate the efficacy on vasodilation. Firstly, the influence of the single 
agents was tested on cell viability in a time-course study (from 30sec to 300sec) on H9c2 and 
PAE cells. The range of concentration of the single agents was reported to exert biological 
effects: from 2.5μM to 50μM for Q10, from 2.87mM to 11.5mM for L-arginine and from 10nM 
to 1μM for vitD [172, 235]. Q10 and vitD were prepared in ET-OH100%, then diluted in sterile 
saline 0.9% solution and then directly added to the culture medium to obtain the final 
concentration reported above; L-arginine was directly dissolved in sterile saline 0.9% and then 
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directly added to the culture medium to obtain the final concentration reported above. 
Secondly, the cooperative activity was demonstrated adding all agents at the same time (QLD) 
to analyze cell viability, NO production and ROS production on both cell lines. Finally, the 
intracellular pathways involved by single agents and QLD were studied by Western blot 
analysis. In addition, the inhibitors (100nM wortmannin, 10μM UO126 and 10mM L-NAME 
administered 30min before the QLD addition) [181] of intracellular pathways were tested on 
NO production, to verify the mechanism of action. 
In in vivo experiments, 130 male Wistar rats (weighing 350 to 400g) were used to study blood 
flow, NO and ROS production, SOD activity and intracellular pathways. Rats were randomized 
into 4 groups: n=115 to evaluate time-course (from 30 to 300sec) of single agents for each 
concentration including untreated rats and solvent alone; n=10 to study QLD; n=5 to study 
ischemia, n=10 to study QLD after ischemia induction. 
Dose selection was based on observations from in vitro experiments and upon a study on the 
translation of doses from animal to human [241]. Thus, Q10 administration resulted in 12.5mg 
for in vitro experiments and 50mg in in vivo experiments. Similarly, L-arginine administration 
was 0.5g and 2g respectively and vitD was 1.25μg and 5μg respectively. The agents 
administered in rats were prepared in 750µl of sterile saline 0.9% solution in a similar manner 
to what reported in in vitro experiments. Blood samples were obtained from the abdominal 
aorta with a sterile syringe containing 50 lL of heparin (100 United States Pharmacopeia 
units/mL; Sigma). Finally, abdominal aorta tract was removed immediately and placed into 
lysed buffer for Western blot analysis and stored at -80°C till to extractions. 
● Project 4 (brain line of research) 
Primary astrocytes were used to study oxidative stress and iron-dependent damage that are two 
different biological aspects involved in brain ageing and neurodegeneration. 
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The role of vitD and LA under physiological condition was analyzed in the first set of 
experiments. In this step, the dose- and time-dependent studies (from 15min to 1440min) on 
cell viability were performed with LA (from 10μM to 100μM) to determine its optimal 
concentration, and then this concentration (50μM) was maintained in all successive 
experiments. Then the combination with 50μM LA and 100nM vitD [242, 243] was 
investigated in a time-course study (from 15min to 1440min) and then by the permeability 
assay to determine each specific concentration through BBB. In a second set of experiments, 
the role of oxidative stress was investigated by pretreatment for 30min with 200μM H2O2 on 
astrocytes [244]. Through MTT test the ability of vitD and LA alone and combined to prevent 
or restore the damage caused by oxidative stress was analyzed. Moreover, mitochondrial 
membrane potential measurement, amyloid precursor protein (APP) quantification, and 
Western blot analysis were performed at 24h. In a third set of experiments, to induce 
neurodegeneration, cells were pretreated with catalytic iron (Fe3+) 300μM for 6 days [245] and 
then treated with vitD and LA alone and combined for additional 6 days to investigate the 
protection exerted by the combination, analyzing viability, ROS production, iron 
concentration, APP quantification and activated intracellular pathways. 
  
3.4 Cell viability 
The non-cytotoxic effects of vitD combined with other agents were investigated using MTT 
test, basing on the conversion of water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) compound to an insoluble formazan product. The measured 
absorbance at OD 570nm is proportional to the number of viable cells. The MTT assay can be 
used for determined the cytotoxicity of chemically active drugs or substances e potentially 
toxic. The intensity of the color of the solution obtained is directly proportional to the 
concentration of formazan and is corresponding to the vitality of the biological sample. MTT-
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based In Vitro Toxicology Assay Kit (Sigma-Aldrich) was performed as described in literature 
[45] to determine cell viability after stimulations. Cells were incubated in DMEM without red 
phenol 0% FBS with 1% MTT dye for 2h at 37°C in incubator and then cell viability was 
determined measuring the absorbance through a spectrophotometer (VICTOR X4 multilabel 
plate reader) at 570nm with correction at 690nm. The results were obtained comparing the 
results to control cells (100% viable). This technique has been used in all Projects (1 to 4). 
  
3.5 Agents preparation  
In Project 2, alginates combined with vitD was used to prepare a commercial product (named 
Aquilea Reflux®, Laborest Italia srl, Milan, Italy; Aq) used as a dietary supplement indicated 
to counteract high acidic conditions thanks to its specific composition [45]. Aq is a dietary 
supplement combining the properties of calcium alginate with a tyndalized probiotic 
(Pylopass®) and an extract of prickly pear and olive leaves (Mucosave®) in a buffer solution. 
It is composed of Mucosave® (0.83mg/ml), calcium alginate (1.66mg/ml), magnesium 
hydroxide (2.66mg/ml), potassium citrate (4.66mg/ml), Pylopass® (0.66mg/ml) and vitamin 
D3 (0.000083mg/ml). It was dissolved according to solubility information reported in 
manufacturer’s instructions, directly in the DMEM without red phenol and FBS but 
supplemented with 1% penicillin/streptomycin, 2mM L-glutamine and 1mM sodium pyruvate 
(white medium). 
A mixture of polysaccharides and flavonoids present as a commercial product (Neobianacid®, 
Aboca, Italy; Neo), is a product that improves the protection of the stomach and the esophagus 
thanks to the presence of Poliprotect® and a flavonoid fraction (Matricaria recutita and 
Glycyrrhiza glabra). This product was dissolved following the manufacturer’s instructions 
directly in white medium and added without dilution to the cells. Diclofenac (D) and 
Pantoprazole (P) were prepared directly in white medium and added to the cells at final 
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concentrations of 250μM and 10μM respectively, as reported in literature [118, 246] before or 
after Aq or Neo in presence or absence of hyperacidic condition. HCl was used to prepare an 
acidified medium (pH 4) that was added to the cells without dilution. To create a hyperacidic 
condition, before stimulation 1:172 (%v/v) of HCl were also administered to the samples. 
  
3.6 Blood-Brain Barrier Experimental Model 
The blood-brain barrier (BBB) controls the passage of substances between the blood and the 
central nervous system (CNS) and it is a dynamic biological interface, for this reason we used 
this model on Project 4.  
Astrocytes were cocultured with HUVEC cells according to methods reported in literature 
[247]. In brief, 4×104 astrocytes/cm2 were plated on the basolateral side of the flipped 6.5mm 
Transwells with a polyester membrane with 0.4μm pore size (Corning Costar, Sigma-Aldrich) 
and left to attach for 4h. Transwells were then placed into the normal orientation and the cells 
left to grow for 48h. After this time, 1×105 HUVEC cells/cm2 were plated in the apical 
compartment. The inserts were then placed in a 24-well plate. After 7 days of culture, the 
Transwells were treated, and permeability studies were performed [248]. To understand the 
ability of tested substances to cross the blood-brain barrier, the medium at the bottom side of 
the Transwells was quantified over time (from 15min to 1440min) by measuring the volume 
and the concentration of vitD and LA. 
 
3.7 ROS Production 
ROS production were analyzed on all Projects (1 to 4) to evaluate oxidative stress condition 
modified by the stimulation with vitD alone or combined with other agents. The rate of 
superoxide anion production was determined as a superoxide dismutase-inhibitable reduction 
of cytochrome C, following a standard technique [242]. 100μl of cytochrome C were added in 
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both treated and untreated cells and in another sample, 100μL of superoxide dismutase were 
also added for 30min in incubator (all substances from Sigma-Aldrich). After that, the 
absorbance was measured at 550nm using a spectrophotometer (VICTOR X4 Multilabel Plate 
Reader) and the O2 was expressed as nanomoles per reduced cytochrome C per microgram of 
protein. In addition, only in Project 1, we investigated the effects also on plasma samples. The 
concentration of ROS in plasma was measured in a 96-well plates using the Antioxidant Assay 
kit (Cayman) following the manufacturer’s instructions [249]. 10μl of Metmyoglobin and 
150μl of Chromogen per well were added in plasma and standard samples (Trolox in Assay 
buffer from 0mM to 0.33mM) and the reactions started adding 40μl of Hydrogen Peroxide 
Working Solution to all the wells. The 96-well plate was covered, mixed for 5min at room 
temperature and the absorbance was measured using spectrophotometer (VICTOR X4 
Multilabel Plate Reader) at 750nm or 405nm. The results were expressed as means ±SD (%). 
  
3.8 SOD Activity Assay 
Superoxide dismutase (SOD) has been measured by Cayman’s Superoxide Dismutase Assay 
Kit basing on detection of superoxide radicals generated by xanthine oxidase and 
hypoxanthine. The SOD assay measures the three types of SOD (Cu/Zn, Mn, and FeSOD). The 
cells and tissue were lysed after treatments following manufacturer’s instructions. In a 96 well, 
10μl were added 200μl of the diluted Radical Detector in samples. At the same time, a standard 
curve was prepared (0.05–0.005 U/ml). Then, 20μl of diluted Xanthine Oxidase were added at 
all wells and the plate mixed for 30min at RT and then the absorbance measured through a 
spectrometer (VICTOR X4 multilabel plate reader) at 480nm. The results were expressed as a 
means (%) compared to control. This technique has been used in both Project 1 and 3. 
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3.9 Griess Assay  
In Project 3, NO production was measured at the end of stimulations through Griess method 
(Promega, Milan, Italy) in a 96-well plate on both cell lines maintained in DMEM 0% FBS 
without red phenol, as previously described [250-252]. In addition this assay was also used to 
measure the level of NO production on plasma sample, as previously described [251, 252] and 
following the manufacturer’s instructions.  
Briefly, samples were mixed with Sulfanilamide Solution and incubated for 5–10 minutes at 
room temperature, protected from light. 
After that, NED Solution was added to all wells and incubated for 5–10 minutes at room 
temperature, protected from light. 
The absorbance were measured through a spectrophotometer (VICTOR X4 multilabel plate 
reader) at 550nm. NO concentration is determined by comparison of values to the Nitrite 
Standard reference curve. 
  
3.10 Akt/ERK Activation Assay 
The InstantOne™ ELISA is specifically engineered for accurate measurement of 
phosphorylated ERK 1/2 and AKT in cell lysates, following the manufacturer’s instructions 
(Thermo-Scientific). Cells at the end of each treatments were lysed with 100μL Cell Lysis 
Buffer Mix, shaken for 10min at RT and 50μL/well of each sample were tested in InstantOne 
ELISA microplate strips including the 50μL/well Positive Control Cell Lysate and 50μL/well 
negative control. At each well 50μL of prepared Antibody Cocktail were added and the strips 
incubated for 1h at room temperature on a microplate shaker and washed 3 times with 
200μL/well of Wash Buffer (1X). At the end, 100μL of the Detection Reagent were added to 
each well and after 20min the reaction was stopped adding to each well 100μL of Stop Solution. 
The strips were measured by a spectrometer (VICTOR X4 multilabel plate reader) at 450nm. 
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The results were expressed as means Absorbance (%) compared to control. This technique has 
been used in Project 1, 2 and 4. 
  
3.11 Mitochondrial Membrane Potential 
The mitochondrial membrane potential was analyzed on Project 4 by the Oxygen 
Consumption/Mito membrane Potential Dual Assay Kit (Cayman Chemical Company) 
following manufacturer's instructions [253]. The mitochondrial membrane potential was 
measured using JC-1 that at low concentrations (due to low mitochondrial membrane 
potential), it is predominantly a monomer that yields green fluorescence with emission of 
530±15nm. At high concentrations (due to high mitochondrial membrane potential), the dye 
aggregates yielding a red to orange colored emission (590±17.5nm). Therefore a decrease in 
the aggregate fluorescent count is indicative of depolarization whereas an increase is indicative 
of hyperpolarization. The results are expressed as means ±SD (%) compared to control cells. 
  
3.12 ATP Assay  
In Project 2, at the end of each stimulation the medium was removed and the cells were 
immediately treated with the components of the ATP assay kit (nucleotide releasing buffer, 
ATP monitoring enzyme, enzyme reconstitution buffer, ATP), following the manufacturer’s 
instructions. Luminescence was measured 1 min after the addition of ATP monitoring enzyme 
in a VICTORX4 multilabel plate reader (PerkinElmer Waltham, Massachusetts, U.S.A.), and 
luminescence was expressed as means ±SD% of μmol of ATP/g protein [254]. 
  
3.13 p53 Activity 
In Project 2, p53 activity was measured by specific ELISA kit (p53 transcription factor assay 
kit, Cayman Chemical, Ann Arbor, Michigan, USA), examining the nuclear extracts obtained 
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at the end of each stimulation following the manufacturer’s instructions. The nuclear extraction 
was obtained by classical technique using a complete buffer present in the kit. Briefly, the cells 
were lysed with ice-cold 1X Complete Hypotonic Buffer, supplemented with NP-40 and then 
centrifuged at 12.000g at 4°C for 10 minutes. The pellet was solubilized with icecold Complete 
Nuclear Extraction Buffer 1X supplemented with protease and phosphatase inhibitors, and then 
centrifuged at 12.000g for 15 minutes at 4°C; the supernatant was examined to analyse the 
activity of p53 related to the protein quantification through BCA assay (Thermo Fisher). This 
technique has been used also in Project 4 after properly stimulation. 
  
3.14 RES Quantification 
RES quantification in CHO-K1 cells, rat plasma and tissue samples (liver, stomach, intestine, 
heart, kidneys and ovaries) was carried out by HPLC-MS analysis. 
At the end of stimulations cells were placed in ice and supernatants were collected in 1.5ml 
centrifuge tubes to determine the rate of extracellular RES. 1×106 CHO-K1 cells at the end of 
stimulations were washed with cold 0.9% saline solution, lysed in ice 0.9% saline solution, 
mixed for 10min at 4°C and centrifuged for 20min at 13000 rpm at 4°C. Supernatants were 
used for quantification of intracellular RES. Samples were diluted with equal volume of 
acetonitrile, vortexed, centrifuged at 13000 rpm for 10min and analyzed by HPLC-UV. Tissues 
were homogenized in a volume of 100mg tissue/300μl of ice 0.9% saline solution (w/v) at 1600 
rpm for 2min and the lysates were mixed for 20min at 4°C, and then centrifuged at 13000 rpm 
for 30min at 4°C. Plasma and tissue supernatants were processed as follows. An aliquot of 50μl 
of plasma or tissue sample was mixed with 50μl of 1M of sodium acetate buffer (pH = 5.5) and 
2.5μl of β-glucuronidase/arylsulfatase from Helix pomatia in a 1.5ml centrifuge tube. Ethyl 
acetate (600μl) was added, then sample was extracted by vortexing (40s), and centrifuged at 
13000 rpm for 10min. An aliquot (550μl) of the organic layer was transferred into 1.5ml 
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centrifuge tube and evaporated at 45°C under reduced pressure for 40min. The residue was 
dissolved in 100μl of acetone containing the IS (trans-4-hydroxystilbene- final concentration, 
200μg/l), 25μl of 0.1N NaOH, and 100μl of 1mg/ml Dns-Cl (dansyl chloride) solution in 
acetone. Sample was shortly vortexed and heated at 45°C for 20min. After centrifugation 
(13000 rpm for 5min) the sample was analysed by HPLC-MS. Calibration curve for RES 
quantification was prepared by spiking blank matrixes and processed as described above, 
except for the addition of β-glucuronidase/arylsulfatase. 
  
3.15 Vitamin D Quantification 
In order to quantify the concentration of vitD on plasma and cells, we have been used two 
different assays. 
●  Project 1 (ovarian line of research) 
The competitive EIA assay kit has been used to detect both 25(OH)D3 and 25(OH)D2 
(Cayman’s Vitamin D EIA Kit) in plasma samples. At the end of each time point, plasma 
samples were collected using EDTA-Na2 as an anticoagulant, centrifuged for 15min at 1000×g 
at 4°C within 30min and then the supernatant used immediately. Before adding to wells, the 
SABC working solution and TMB substrate were equilibrate for at least 30min at room 
temperature and the strips of the plate washed twice before adding standard, sample and 
control. For the quantification it is necessary to plot a standard curve including control (zero 
well). 0.1ml of each sample and standard were added into test sample wells, the plate sealed 
with a cover and incubated at 37°C for 90min. After that the plate content was removed and 
0.1ml of Biotin-detection antibody work solution was added into the standard and test sample 
for 60min at 37°C. After the plate was washed 3 times with Wash buffer 0.1ml of SABC 
working solution into each well was added and the plate incubated at 37°C for 30min. After 
the plate was washed 3 more times with Wash buffer 90μl of TMB substrate into each well was 
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added and the plate incubated at 37°C in dark within 15–30min. After this time 50μl of Stop 
solution into each well was added and the absorbance measured at 450nm in a microplate reader 
immediately after adding the stop solution. 
● Project 4 (brain line of research) 
The competitive ELISA assay kit (FineTest) has been used to detect the metabolically active 
form of vitD. At the end of each stimulation, 50μl of each sample was collected and 
immediately used, following the manufacturer's instruction. Then, 50μl of biotin-detection and 
100μl of SABC working solution were added and incubated at 37°C for 30min at each sample. 
At the end the supernatants were discarded, and then 90μl TMB substrate plus and 50μl of stop 
solution were added. Finally, the 96-well plate was analyzed by a spectrometer at 450nm 
(VICTOR X4, multilabel plate reader). In addition, it was necessary to plot a standard curve 
including the background (zero well) to perform a quantification. 
  
3.16 Lipoic Acid Determination 
The concentration of LA which crossed to BBB was measured  (Project 4) as described in 
literature [255]. At the end of stimulations, the basolateral volume was analyzed through a 
spectrometer (VICTOR X4, multilabel plate reader) at 320nm, and the absorbance related to 
the standard curve was obtained from LA (200ng/ml). The results were expressed as means 
±SD (%) of absorption, normalized to the control. 
  
3.17 Amyloid Precursor Protein (APP) Quantification 
Amyloid precursor protein (APP) quantification (Project 4) was measured by the Amyloid 
Beta A4 protein ELISA kit (Sigma-Aldrich) on cellular supernatants following the 
manufacturer's instructions. Briefly, at the end of treatments, cellular supernatants were 
collected and each sample was tested with the ELISA kit. The biotinylated detection antibody 
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specific for the target protein was added in each well and the plate was incubated for 1 hour at 
room temperature. Then, after 45 minutes of incubation with HRP-conjugated streptavidin, 
TMB substrate solution was added for 30 minutes, and subsequently, the reaction was stopped 
by adding stop solution. APP concentration was determined by measuring the absorbance 
through a spectrometer (VICTOR X4, multilabel plate reader) at 450nm and calculated by 
comparing results to the APP standard curve. 
  
3.18 Iron Quantification Assay  
In Project 4, the Iron Assay Kit (Sigma-Aldrich) which measures ferrous iron (Fe2+), ferric 
iron (Fe3+), and total iron (total iron–ferrous iron) in samples was used on astrocytes following 
the manufacturer's instructions [256]. The absorbance at 593nm was measured by a 
spectrometer (VICTOR X4, multilabel plate reader). Ferric iron concentrations are equal to the 
total iron (sample plus iron reducer)-Fe2+ (sample plus assay buffer). The iron concentration 
was expressed as ng/ml. 
  
3.19 Western Blot   
In order to investigate the intracellular pathways activated by vitD and other agents, Western 
blot and densitometric analysis were performed. 
● Project 1 (ovarian line of research) 
CHO-K1 cells were lysed in ice Complete Tablet Buffer (Roche) supplemented with 2mM 
sodium orthovanadate, 1mM phenylmethanesulfonyl fluoride (PMSF; Sigma-Aldrich), 1:50 
mix Phosphatase Inhibitor Cocktail (Sigma-Aldrich) and 1:200 mix Protease Inhibitor Cocktail 
(Calbiochem). 35μg of proteins of each sample were resolved on 10% SDS-PAGE gel. 
Polyvinylidene difluoride membranes (PVDF, GE, Healthcare Europe GmbH, Milan, Italy) 
were incubated overnight at 4°C with specific primary antibody: anti-VDR receptor (1:400, 
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Santa-Cruz) and anti-ERβ (1:500, Santa-Cruz). Protein expression was normalized to the 
specific total protein (if possible) and verified through β-actin detection (1:5000; Sigma-
Aldrich) and expressed as a mean ±SD (%). 
In addition, ovarian tissues were immediately washed with ice 0.9% saline solution (w/v), 
weighed and homogenized in a volume of 100mg tissue/300μL of lysis buffer (0.1 M Tris, 0.01 
M NaCl, 0.025 M EDTA, 1% NP40, 1% Triton X100, Sigma-Aldrich, Milan) supplemented 
with 2mM sodium orthovanadate, 0.1M sodium fluoride (Sigma-Aldrich, Milan), 1:100 mix of 
protease inhibitors (Sigma-Aldrich, Milan), 1:1000 phenylmethylsulfonyl fluoride (PMSF; 
Sigma-Aldrich, Milan), using an electric potter at 1600 rpm for 2min. Samples were mixed for 
30min at 4°C, centrifuged for 30min at 13000 rpm at 4°C and 40μg of proteins for each samples 
resolved on SDS-PAGE gel at 15%. Proteins transferred to polyvinylidene fluoride membranes 
(PVDF, GE Healthcare Europe GmbH, Milan, Italy) were incubated  with specific primary 
antibody, overnight at 4°C: anti-VDR receptor (1:400, Santa-Cruz), anti-ERβ (1:500, Santa-
Cruz), anti-cyclin-D1 (1:1000, Euroclone, Milan, Italy). Protein expression was normalized 
and verified through β-actin detection (1:5000; Sigma-Aldrich) and expressed as a mean ± SD 
(%). 
● Project 2 (gastric line of research) 
After each stimulation, the cells were washed with iced PBS 1X supplemented with 2mM 
sodium orthovanadate (Sigma-Aldrich, Milan, Italy) and lysed in iced Ripa Buffer (10mM 
Na2HPO4, 150mM NaCl, 2mM EDTA, 1% NP-40, 0.1% sodium dodecyl sulphate, 1% sodium 
deoxycholate, 50mM sodium fluoride; Sigma-Aldrich, Milan, Italy) supplemented with 2mM 
sodium orthovanadate (Sigma-Aldrich, Milan, Italy), 1:1000 phenylmethanesulfonyl fluoride 
(PMSF; Sigma-Aldrich, Milan, Italy) and 1:100 protease inhibitors cocktail (Sigma-Aldrich, 
Milan, Italy). 35μg of proteins were resolved on 10% SDS-PAGE gels (SDS-PAGE; Bio-Rad 
Laboratories, Hercules, CA, USA), transferred to polyvinylidene fluoride membranes (PVDF, 
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GE Healthcare, Milan, Italy) anti-VDR (1:250, Santa-Cruz) which were incubated overnight at 
4°C with specific antibodies: anti-p53 (1:400, Santa-Cruz), anti-Annexin V (1:1000, Sigma-
Aldrich, Milan, Italy), and anti-Ki67 (1:800,Santa-Cruz), The protein expressions were 
normalized and verified through β-actin detection (1:5000; Sigma-Aldrich, Milan, Italy). 
• Project 3 (cardiovascular line of research) 
After stimulations, H9c2 and PAE cells were washed with iced PBS 1X (Sigma) supplemented 
with 2mM sodium orthovanadate (Sigma) and lysed in ice with Complete Tablet buffer (Roche) 
supplemented with 2mmol/L sodium orthovanadate and 1:1000 
phenylmethanesulfonylfluoride (PMSF; Sigma-Aldrich). 40μg from each lysate were resolved 
on 10% SDS-PAGE gels (SDS-page, Bio-Rad Laboratories, Hercules, CA, USA), transferred 
to polyvinylidene fluoride membranes (PVDF, GE Healthcare Europe GmbH, Milan, Italy) and 
incubated overnight at 4°C with specific primary antibody: anti-phospho-AktSer473 (1:1000; 
Cell Signaling Technologies, Beverly, MA, U.S.A.); anti-Akt (1:1000; Cell Signaling 
Technologies, Beverly, MA, U.S.A.); anti-phospho-p44/42thr202tyr204 (1:1000; Cell Signaling 
Technologies, Beverly, MA, U.S.A.); anti-p44/42 (1:1000; Cell Signaling Technologies, 
Beverly, MA, U.S.A.); anti-phospho-eNOSser1177 (1:1000; Cell Signaling Technologies, 
Beverly, MA, U.S.A.); anti-eNOS (1:1000; Cell Signaling Technologies, Beverly, MA, 
U.S.A.); anti-p53 (1:250; Santa-Cruz Biotechnology, Dallas, Texas, U.S.A.); anti-VDR (1:250; 
Santa-Cruz Biotechnology, Dallas, Texas, U.S.A.). Protein expression was normalized and 
verified through ß-actin detection (1:5000; Sigma, Milan, Italy). 
• Project 4 (brain line of research) 
Cells were washed and then lysed in the ice Complete Tablet buffer (Roche) supplemented 
with 2mM sodium orthovanadate, 1mM phenylmethanesulfonyl fluoride (PMSF; Sigma-
Aldrich), and 1:100 mix Protease Inhibitor Cocktail (Sigma-Aldrich). From each lysate, 35μg 
proteins was resolved into 8% and 15% SDS-PAGE gels, and polyvinylidene difluoride 
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(PVDF) membranes (GE Healthcare) were incubated overnight at 4°C with a specific primary 
antibody: anti-SOD3 (1 : 250, Santa Cruz), anti-phospho-PKAα/β/γThr198 (1 : 250, Santa Cruz), 
anti-NOS2 (1 : 250, Santa Cruz), and anti-cytochrome C (1 : 1000, Calbiochem). Protein 
expression was normalized and verified through β-actin detection (1 : 5000; Sigma-Aldrich) 
and expressed as a mean ±SD (% vs. control). 
  
3.20 Statistical Analysis 
In vitro results obtained from at least 5 independent experiments conducted in triplicates were 
expressed as means ±SD, using One-way ANOVA followed by Bonferroni post hoc test or the 
Mann-Whitney U test, to compare percentages of responses. Values of significance for p<0,05 
were considered statistically significant (Project 1, 2, 3 and 4). Data collected from in vivo 
results obtained from 4 independent experiments were analyzed by two-way ANOVA and one-
way ANOVA followed by Bonferroni post hoc test and the comparisons between the two 
groups were performed using a two-tailed Student’s t-test. Multiple comparisons between 
groups were analyzed by two-way ANOVA followed by a two-sided Dunnett post-hoc testing. 
P-value<0.05 was considered statistically significant (Project 1 and 3). 
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4. Results  
In order to explore the effects on different cell types of viD and other agents, the results has 
been subdivided following the Project order (from 1 to 4) 
● 4.1 Project 1 (ovarian line of research) 
The results of this project are contained in the paper: Biological effects of combined resveratrol 
and vitamin D3 on ovarian tissue. Uberti F, Morsanuto V, Aprile S, Ghirlanda S, Stoppa I, 
Cochis A, Grosa G, Rimondini L, Molinari C. J Ovarian Res. 2017;10(1):61.  
 
Dose-Response and Time-Course Study with Resveratrol in CHO-K1 Cells 
To identify the dose of RES able to induce the maximal effect on cell viability during time, a 
dose response and a time-course study were planned. Moreover, these experiments were 
important to understand the cooperative effect of RES with vitD during time. As shown in Fig. 
1c, RES 50μM appeared to be the dose producing the greatest effect (p<0.05) compared to 
control and to other concentrations (10, 25, 100μM) during all time periods considered (Fig. 
1a–d). This concentration of RES was maintained for all successive experiments. In addition, 
another important finding regarded the reaction time of RES 50μM, which appeared as a 
biphasic curve that quickly started (at 2min), confirming its rapid metabolism. Its beneficial 
effect was maintained as long as 3 h. 
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Fig. 1 
Time-course and dose-response study of CHO-K1 viability measured by MTT test. a time-
course of RES 10μM; b time-course of RES 25μM; c time-course of RES 50μM; d time-course 
of RES 100μM. Reported data are means ±SD of five independent experiments. *not 
significant vs control; point without symbol p < 0.05 vs control. RES=resveratrol. The effect 
of solvent alone is reported as well. 
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The combination of RES 50μM with vitD 100nM was able to amplify biological effects with a 
similar kinetic reaction to RES alone (p<0.05); vitD was already able to enhance the effect of 
RES from 2min of treatment (Fig. 2a). Then we observed a stable plateau phase around 6h and 
then effects began to decline for the following 48h. For this reason, we have chosen to study 
the kinetics ranging from 2min to 3h for all successive experiments. As shown in Fig. 2b, the 
ROS produced by RES alone and combined with vitD appeared to be modulated during time. 
In particular, in the first minutes (from 2 to 15min) a significant ROS production compared to 
control (p<0.05) was observed after treatment with RES alone and the presence of vitD was 
able to amplify this effect. This combination was also able to maintain a reduction of ROS up 
to 1h of stimulation (p<0.05); at 3h ROS production was comparable to control (p>0.05). These 
data on cell viability of CHO-K1 cells confirm the beneficial effects observed and the 
importance of the combination of RES and vitD in maintaining the beneficial effects of RES 
during time. 
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Fig. 2 
The cooperative effect of RES and vitD during time on cell viability and ROS production in 
CHO-K1 cells. a cell viability and b ROS production measured during time-course study in 
presence of RES and vitD alone and combined. Reported data are means ±SD in (a) and they 
are expressed as means ±SD(%) in (b) of five independent experiments. *not significant vs 
control; points without symbol, p<0.05 vs control. RES=resveratrol 50μM; vitD=vitamin D3 
100nM; RES+vitD=co-stimulation of RES 50μM with vitD 100nM. 
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Quantification of Intracellular Resveratrol with or without Vitamin D3 in CHO Cells 
Since the biological effects of RES were due to its ability to be absorbed in cells and tissues, 
the intracellular concentration of RES in CHO-K1 during time was determined by HPLC-UV. 
As reported in Fig. 3, the absorption rate of RES combined with vitD was enhanced compared 
to RES alone (p<0.05), in particular in the first 15min of stimulation; the maximum effect was 
observed at 5min of stimulation (about 16.7μM). These findings confirmed previous data about 
the cooperative effect of RES combined with vitD; indeed, vitD was important to amplify the 
effects of RES influencing also the level of RES uptake in ovarian cells. Finally, the time range 
from 2 to 15min of stimulation was used to verify the intracellular cascade activated by RES 
alone and combined with vitD. 
 
 
 
 
 
 
Fig. 3 
Measure of intracellular concentration of RES alone and combined with vitD in CHO-K1 cells 
in a time-course study. Reported data are means ±SD of five independent experiments. *not 
significant vs control; points without symbol, p<0.05 vs control. RES=resveratrol 50μM; 
RES+vitD=co-stimulation of RES 50μM with vitamin D 100nM. 
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Analysis of the Main Intracellular Pathways Activated by Resveratrol and Vitamin D3 
In order to assess which intracellular pathways were activated after intracellular uptake of RES 
alone and combined with vitD, ERKs, Akt, SOD, ERβ and VDR signaling were investigated 
in CHO-K1 cells. As reported in Fig. 4a and b, the role of ERK/MAPK and PI3K/Akt pathways 
was examined to explain the action mechanism of RES alone and combined with vitD; MAPK 
and PI3K signal transduction pathways are closely associated with the one of healthy tissue. 
To study changes in the activation levels of proteins associated with cellular signal transduction 
according to treatment time, ELISA was performed following treatment for various time 
periods up to 15min. The results confirmed an increase in activation of ERK and Akt due to 
RES alone and these effects were amplified by the use of vitD. In particular, the results showed 
that the activation levels of ERK and Akt started at 2min and the maximum effect was observed 
at 5min in both RES alone and combined with vitD compared to control (p<0.05) then 
decreased. These data confirmed the importance of vitD in amplifying the beneficial effects of 
RES to maintain healthy tissue. In addition, since the beneficial effects of RES included its 
anti-radical action, two important mechanisms involved such as SOD activity and ERβ, were 
also investigated by ELISA and Western blot respectively. As reported in Fig. 4c, RES 
combined with vitD is able to maintain ROS production low during time maintaining SOD 
activity similar to control. In addition, these anti-oxidant effects were obtained via ERβ 
activation (Fig. 4d); the involvement of ERβ was observed starting from 2min after treatment 
with RES alone and increasing after 5min compared to control (p<0.05); the presence of vitD 
amplified (p<0.05) all these levels of activations (about 20% at 2min and 65% at 5min of RES 
plus vitD compared to RES alone), indicating a cooperative activity exerted by RES and vitD. 
The importance of combined treatments with RES and vitD was also confirmed on VDR 
expression (Fig. 4e), in which a stable activation of VDR during time was observed (p<0.05), 
indicating its involvement in the beneficial effects previously observed.  
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These results indicate that RES is able to maintain tissue health through ERK, Akt, SOD, ERβ 
and VDR signal transduction pathways, which can help clarify that these beneficial effects 
exerted by vitD are a necessary condition. 
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Fig. 4 
Western Blot, densitometric analysis and protein activation of CHO-K1 cells stimulated with 
RES and vitD alone and together. In a (ERK/MAPK), b (Akt), c (SOD) activations by ELISA 
are reported as means ±SD(%) of five independent experiments. In d (ERβ receptor) and e 
(VDR receptor) Western blot (on the left) and densitometric analysis (on the right) are reported. 
In the right column the specific densitometric analysis is reported and expressed as means 
±SD(%) of five independent experiments. *p<0.05 vs control; **p<0.05 vs RES alone; φp<0.05 
vs vitD; the bars, p<0.05 between RES+vitD at different times. RES=resveratrol 50μM; 
vitD=vitamin D3 100nM; RES+vitD=co-stimulation of RES 50μM with vitD 100nM. 
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Bioavailability of Resveratrol with Vitamin D3  
Some additional experiments were performed to demonstrate the efficacy of RES and vitD also 
in in vivo study, given their biological effects reported in an in vitro study. Starting from 
bioavailability of RES alone and combined with vitD, following a time-course experiments (2, 
5, 60, 180, 360, 720min).  As reported in Fig. 5a on rat plasma samples, the concentration of 
RES plus vitD and RES alone followed by a biphasic curve and it is time-dependent. At 2min 
(p<0.05) plasma concentration started to enhance.  
The plasma of rats treated with RES alone showed a second peak of RES concentration at 1h 
of treatment (about 20% lower than 2min) and then the concentration decreased reaching 
control values. The presence of vitD significantly amplified the absorption rate of RES already 
in the first 2min (about 34% compared to RES alone at 2min) and obtained the maximum 
effects at 5min (about 220% compared to RES alone at 5min).  
In addition, a second peak was extended in time (after 1h) because the absorption rate after 
5min was similar to what observed with RES alone as long as 3h. At 6h the plasma 
concentration decreased leading to control values after a second peak. This finding about the 
second peak supported the hypothesis that RES can be stored in organs to explain a secondary 
effect in the long run.  
All these data explain the role of vitD in supporting the biological activity of RES and support 
the importance of the cooperative activity of RES and vitD. As reported in Fig. 5b, during time 
the quantification of vitD in plasma samples showed an increase in quantity of vitD present in 
plasma when vitD is administered with RES.  
After oral intake these data confirmed the mutual influence of RES and vitD on the absorption. 
In addition, the ROS concentration assessment in plasma of rats confirmed a positive influence 
of vitD in counteracting oxidative stress with RES (Fig. 5c) during time; a slow and progressive 
decrease starting from 1h of treatment with RES combined with vitD was observed and this 
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effect is aligned with the absorption test at the time the maximum absorption rate has been 
reached. All these data explained the ability of RES plus vitD to rapidly cross the membrane 
and to reach target tissues. 
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Fig. 5 
Bioavailability, vitamin D quantification and ROS production in in vivo experiments. Female 
rats (n = 48) were treated with RES 0.5mg alone (n = 24), combined with vitD 0.4μg (n = 24) 
and with vitD 0.4μg alone (n = 18) by gavage. The animals were sacrificed at specific time-
points (ranging 2–270min) and plasma samples were collected. In a RES plasma concentration 
(μg/L), in b vitD plasma quantification and in c the ROS production are reported. The results 
are expressed as means ±SD in panel (a-b) and as means ±SD(%) in panel (c) of 4 independent 
experiments. All data p<0.05 vs control. RES=resveratrol 0.5mg; RES+vitD=preparation 
composed of RES 0.5mg and vitD 0.4μg. 
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Analysis of Intracellular Pathways Activated by Resveratrol and Vitamin D3 in Ovarian 
Tissue 
Some intracellular pathways involved in the biological effects of RES and vitD were also 
investigated in ovarian rat tissues in order to clarify the importance of bioavailability after oral 
intake of RES combined with vitD in gynecological disorders during the first minutes (2, 5, 15, 
30min), following the plasmatic changes. As reported in Fig. 6, the involvement of Cyclin D1, 
an important regulator of G1 to S phase progression, demonstrate a better influence of RES 
plus vitD than RES alone (p<0.05) (Fig. 6a and b). The effects of RES plus vitD started at 5min 
compared to RES alone (p < 0.05) and were maintained during time, indicating an improvement 
in cell cycle turn-over, important to maintain the integrity of tissue. This finding was supported 
by a decrease in SOD activity (Fig. 6e) observed with RES combined with vitD as Cyclin D1, 
compared to RES alone. These improvements of the biological effects of RES were obtained 
due to the presence of vitD, supporting previous data on the cooperative effects of these two 
substances. The mechanism activated by RES plus vitD involved both ERβ (Fig. 6a and c) and 
VDR receptors (Fig. 6a and d), as reported. As a matter of fact, RES plus vitD showed the 
strongest effect on ERβ starting from 5min (p<0.05) compared to RES alone and on VDR 
starting from 2min (p<0.05) compared to RES alone. These effects were maintained during all 
time of stimulation. The in vitro results about the cooperative effect of RES and vitD on ovarian 
tissue have been supported by all these findings. 
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Fig. 6 
Western blot, densitometric analysis and protein activity of ovarian tissue obtained from female 
rats (n = 32) treated with RES alone (n = 16) and combined with vitD (n = 16). In the upper (a) 
an example of Western Blot taken at different time (ranging 2–30min) of Cyclin D1, ERβ 
receptor and VDR receptor is reported. In the downstream the specific densitometric analysis 
of Cyclin D1 (b), ERβ receptor (c), and VDR receptor (d) is reported and expressed as means 
±SD(%) of 4 independent experiments. In e SOD activity by ELISA was reported as means 
±SD(%) of 4 independent experiments. *p<0.05 vs control; **p<0.05 vs RES alone; the bars, 
p<0.05 between RES+vitD at different times. RES=resveratrol 0.5mg; RES+vitD=preparation 
composed of RES 0.5mg and vitD 0.4μg. 
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Biodistribution of Resveratrol with Vitamin D3 
The biodistribution and accumulation of RES in different organs during time (30, 60, 180, 360, 
720min), such as heart (Fig. 7a), kidney (Fig. 7b) and liver (Fig. 7c) is another important 
parameter useful to understand the biological effects of RES combined with vitD after oral 
intake and blood concentration. The absorption rate in tissue of RES alone and RES plus vitD 
was different and time-dependent, confirming the hypothesis about the activity of RES in the 
second peak observed in plasma samples. In addition, a better efficacy of RES combined to 
vitD (p<0.05) in creating a tissue deposit of RES was confirmed mainly at 360min in all organs 
tested (p<0.05), indicating the importance of the combination with vitD to exert a systemic 
biological effect. 
 
67 
 
 
 
Fig. 7 
Biodistribution of RES (μg/L) in in vivo experiments. Female rats (n = 40) were treated with 
RES 0.5mg alone (n = 20) and combined with vitD 0.4μg (n = 20) by gavage. The animals 
were sacrificed at specific time-points (ranging 30–270min) and heart (a), kidney (b) and liver 
(c) were collected. The results are expressed as means ±SD (μg/L) of 4 independent 
experiments. *not significant vs control; point without symbol, p<0.05 vs control. 
RES=resveratrol 0.5mg; RES+vitD=preparation composed of RES 0.5mg and vitD 0.4μg. 
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● 4.2 Project 2 (gastric line of research) 
The results reported are contained in the paper: Role of vitamin D3 and alginates in prevention 
of NSAID-dependent cellular injury. Molinari C, Morsanuto V, Ruga S, Stoppa I, Notte F, 
Farghali M, Bozzo C, Castello L, Nardone A, Magnani C, Uberti F. EC Gastroenterology and 
Digestive System 6.3 (2019): 211-223. 
 
Analysis of the Effects of Aq and Neo on Epithelial Gastric Cells Under Oxidative or 
Acidic Conditions 
Both Aq and Neo act as a physical barrier for gastric epithelial cells and exert protection against 
hyperacidity, but the different compositions can determine different beneficial effects. The first 
set of experiments analysed the ability of act before or after the damage caused by oxidative 
stress and acidity of Aq and Neo after 24h of stimulation. As reported in Fig. 8, the effects on 
cell viability and ROS production were different between Aq and Neo alone. Aq induced a 
significant increase in cell viability compared to Neo (about 215%) and to control (p<0.05, see 
figure 8a); Aq also induced a significant reduction in ROS release (about 256%) compared to 
Neo (see fig. 8b). These preliminary data confirmed the hypothesis that the composition can 
influence the efficiency during gastroprotection. In order to clarify the efficacy of Aq and Neo 
in gastroprotection, all the following experiments were performed in presence of pre-treatment 
or post-treatment for 30minutes with 200μM H2O2 or 1:172 (%v/v) HCl. As reported in Fig. 8, 
the pre-treatment with H2O2 or HCl caused a significant reduction (p<0.05) of cell viability and 
an increase of ROS production (p<0.05) compared to control. Aq was able to counteract the 
negative effect exerted by H2O2 or HCl on cell viability (p<0.05) both before and after the 
damage; in particular, the most evident beneficial effects were observed in reversing the 
influence exerted by HCl both on cell viability and ROS production. However, regarding cell 
viability (see Fig. 8a) Aq seems to be more effective when it is added after pre-treatment (about 
100% in oxidative and about 63% in hyperacidic conditions). On the other hand, Neo seems to 
have a beneficial effect only when added after the injury, reported in instructions. Between 
oxidative and hyperacidic pre-treatment conditions, Neo was able to have a greater effect on 
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cell viability when administered in presence of oxidative conditions (about 70% compared to 
hyperacidic conditions). As regards ROS production (see Fig. 8b), that is an important 
parameter to evaluate cellular damage, Aq and Neo had a different effect under oxidative and 
hyperacidic conditions, confirming the differences observed in cell viability. Indeed, both Aq 
and Neo had better results when added after pre-treatment, but Aq had a greater beneficial 
effect on hyperacidic conditions and Neo during oxidative stress. These data confirmed a 
different effect on cell viability and ROS production of Aq compared to Neo and suggest the 
existence of a different mechanism of protection. 
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Fig. 8 
Effects of Aq and Neo during acidic and oxidative stress. In panel (a) cell viability and in panel 
(b) ROS production measured in gastric epithelial cells treated with Aq and Neo for 24h. 
Aq=combination between alginates and vitamin D3, Neo=mixture of polysaccharides and 
flavonoids. Data are expressed as means ±SD (%) of five independent experiments normalized 
to control values (0% line). *p<0.05 vs control; **p<0.05 vs H2O2; ϕp<0.05 vs HCl; arrows 
indicate p<0.05 between different groups. 
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Analysis of the Effects of Aq and Neo to Prevent Cell Death 
Cell death is an energy-dependent process that requires ATP: typically, apoptotic cells exhibit 
a significant decrease in ATP level. This parameter is important in evaluating the effectiveness 
of Aq and Neo to prevent loss of gastric epithelial cells caused by oxidative stress or 
hyperacidity. As reported in Fig. 9a, ATP level was higher in presence of Aq than Neo in basal 
conditions (p<0.05), confirming data observed on cell viability. In addition, treatment with 
200μM H2O2 or 1:172 (%v/v) HCl caused a significant reduction (p<0.05) of ATP indicating 
cell death. Aq was able to counteract the negative effects exerted by H2O2 or HCl on ATP 
production (p<0.05) both before and after the damage, but the best result was observed in 
reversing the influence exerted by pre-treatment with HCl compared to control (p<0.05). Neo 
was able to exert beneficial effects when added after the injury and confirmed a greater effect 
on ATP production when in presence of oxidative conditions compared to control (p<0.05). 
These data support the hypothesis of a different protection mechanism between Aq and Neo. 
Since p53 is a key component for cellular-induced apoptosis through mitochondrial stress 
markers, additional experiments were performed under the same conditions as reported before. 
As reported in Fig. 9b, the activity of p53 induced by Aq and Neo alone was at physiological 
level supported the beneficial effects observed above; moreover, in presence of H2O2 and HCl 
alone, p53 activity significantly increased compared to control, indicating a significant 
mitochondrial stress and a potential activation of the pathway leading to cell death. The ability 
to prevent and restore the damage caused by H2O2 and HCl of Aq (p<0.05) was confirmed: 
indeed, no significant differences were observed between pre and post treatments. Contrary to 
what observed for Aq, Neo was able to prevent and restore the damage caused by H2O2 
(p<0.05), but a little activation was observed with HCl: this data confirms the ability of Neo to 
better counteract the negative effects of oxidative stress during hyperacidic conditions. All 
these results support the hypothesis that Aq and Neo act differently to prevent epithelial 
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stomach cell death. Finally, since the greater effects of Aq were observed in pre-treatment 
conditions with HCl, in all successive experiments only these conditions were maintained. 
 
 
Fig. 9 
Effects of Aq and Neo on apoptotic mechanism. In panel (a) ATP production and in panel (b) 
p53 activation in gastric epithelial cells treated with Aq and Neo for 24h during acidic condition 
or oxidative stress. Aq=combination between alginates and vitamin D3, Neo=mixture of 
polysaccharides and flavonoids. Data are expressed as means ±SD (%) of five independent 
experiments normalized to control values. *p<0.05 vs control; **p<0.05 vs H2O2; ϕp<0.05 vs 
HCl; arrows indicate p<0.05 between different groups. 
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Aq and Neo as Gastroprotective Agents 
Since the chronic use of NSAID can cause gastric ulcers, gastroprotective agents are frequently 
used in combination with anti-acid treatments. However, these agents often do not remove the 
causes of hyperacidity or oxidative stress created by NSAID in the stomach. So today scientific 
research is trying to find new resources of natural origin, especially derived from plants, able 
to reduce gastric cells damage. In this context the effects of Aq and Neo were tested in presence 
of Diclofenac; in particular Aq and Neo were added before and after the stimulation with 
Diclofenac under hyperacidic conditions. As shown in Fig. 10a, in presence of Diclofenac 
alone, cell viability was reduced compared to control (p<0.05), indicating a lower tolerability 
of the cells, and the pre- and post-stimulations with Aq and Neo were able to reduce this 
negative effect. In particular, the greatest effect was obtained using Aq compared to Neo (about 
64%) when added before Diclofenac. On the contrary, during the stimulation after Diclofenac, 
the greatest effect was obtained with Neo compared to Aq (about 40%). These data suggest the 
possible ability of Aq and Neo to be used as gastroprotective agents under hyperacidic 
conditions in a different manner; in particular the best result was observed using Aq compared 
to Neo. This hypothesis was confirmed by comparing data obtained with Aq and Neo on cell 
viability with pantoprazole experiments (P), where similar effect of Aq and Neo preventing the 
loss of cell caused by Diclofenac were observed. It is noteworthy that Aq and Neo added before 
Diclofenac seemed to be more effective than P (p<0.05), indicating Aq and Neo as a new 
possible therapeutic approach. Finally, all these results were confirmed under acidic conditions, 
in which Aq and Neo counteracted the negative effects of Diclofenac better than P (p<0.05). 
In particular, pre-treatment with HCl caused a significant reduction (p<0.05 vs control) in cell 
viability induced by Diclofenac and only Aq was able to prevent (pre-stimulation) and restore 
(post-stimulation) the damage caused by Diclofenac under these conditions (p<0.05 vs control 
and vs Diclofenac), indicating a greater effectiveness of Aq than Neo as a gastro-protector 
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agent. Since a consequence of hyperacidity is the production of oxidative stress, additional 
experiments were carried out to investigate the ability of Aq and Neo to reverse the damage 
acting on ROS release. As reported in Fig. 10b, Diclofenac induced a significant increase 
(about 30%) in ROS production compared to control, confirming its negative effect on cell 
proliferation. Pre-stimulation with Aq was able to significantly reduce the ROS release caused 
by Diclofenac compared to the post-stimulation (about 70% vs post-treatment). Moreover, Neo 
seemed to have greater effects when added after Diclofenac to reduce ROS production (p<0.05, 
about 33% compared to pre-treatment). These data confirm a different ability of Aq and Neo 
to maintain a gastric protection. In addition, comparing the effects of Aq and Neo to P, in 
presence of Diclofenac, the gastro-protection mechanism was confirmed: indeed, Aq and Neo 
had more effectiveness than P (p<0.05). Similar data were observed under acidic conditions, 
in which Diclofenac improved its negative effects and Aq and Neo counteract it (p<0.05) 
exerting greater effects compared to P (p<0.05). As before, Aq had higher effects when added 
before Diclofenac compared to post-stimulation (p<0.05), supporting the idea that it can be 
used as a gastroprotective agent. 
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Fig. 10 
Effects of Aq and Neo alone and combined with Diclofenac during acidic and hyperacidic 
conditions. In panel (a) cell viability and in panel (b) ROS production observed in gastric 
epithelial cells treated for 24h. P=pantoprazole, D=Diclofenac, Aq=combination between 
alginates and vitamin D3, Neo=mixture of polysaccharides and flavonoids. Data are expressed 
as means ±SD (%) of five independent experiments normalized to control values. *p<0.05 vs 
control; **p<0.05 vs HCl; ϕp<0.05 vs Diclofenac; ϕϕp<0.05 vs HCl+Diclofenac; arrows 
indicate p<0.05 between different groups. 
 
 
76 
 
Analysis of Intracellular Pathways Activated by Aq and Neo During Gastro-Protection 
Since the most critical consequence for taking NSAID is hyperacidity, the latter has only been 
further investigated; in order to verify the gastroprotection induced by Aq and Neo, some 
additional experiments were performed to analyse annexin V, p53, Ki67, PI3K/Akt expressions 
and ERK/MAPK activity. As reported in Fig. 11a, annexin V, a marker of nuclear integrity, is 
important to exclude the activation of cell death pathway. Hyperacidic conditions confirmed 
their negative effects (p<0.05 vs control) and Aq and Neo alone, significantly reduced the 
annexin V expression compared to HCl alone (p<0.05). In addition, they were also able to 
counteract the expression of annexin V in presence of Diclofenac: in particular Aq had a better 
result when added before Diclofenac (about 25% vs post-stimulation) and Neo showed its best 
effect when added after Diclofenac (about 23% vs pre-stimulation). In order to confirm the 
protection exerted by Aq and Neo and to exclude a damage leading to cell death, p53 expression 
was evaluated under the same conditions (see Fig. 11b). Also in this case results confirmed the 
negative effects on p53 expression of both hyperacidity and Diclofenac, with an increase of 
about 36% and 32% respectively, compared to control. The positive mechanism activated by 
Aq on hyperacidic condition was able to reduce the activation of p53 caused by hyperacidity 
and Diclofenac (p<0.05): in particular the greater effect was observed when added before 
Diclofenac (about 59% vs Diclofenac). On the contrary, Neo was able to induce a beneficial 
effect when it was added after Diclofenac (about 25% vs Diclofenac), confirming data observed 
previously. Since an important factor for protection against damage, in addition to the 
maintenance of vitality, is the induction of cell proliferation, the Ki67 marker was also studied. 
The expression of Ki67 (see Fig. 11c) in presence of hyperacidic condition or Diclofenac were 
significantly reduced compared to control (p<0.05) and the pre- and post-stimulation with Aq 
reverted these conditions (p<0.05); in particular a greater effect was observed when it was 
added before Diclofenac (about 44% vs post-stimulation), supporting previous data about cell 
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viability. Neo was also able to induce an increase in cell proliferation, but the best result was 
observed when it was administered after Diclofenac (about 50% vs pre-stimulation), indicating 
a different protective mechanism compared to Aq. 
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Fig. 11  
Western blot and densitometric analysis of apoptotic and proliferation pathways during 
hyperacidic condition. In (a) Annexin V, in (b) p53 and in (c) Ki67 expressions analysed 
through Western blot (an example on the left) and densitometric analysis (on the right) of 
gastric epithelial cells treated for 24h. D=Diclofenac, Aq=combination between alginates and 
vitamin D3, Neo=mixture of polysaccharides and flavonoids. All results are expressed as 
means ±SD (%) normalized to control values of five independent experiments. *p<0.05 vs 
control; **p<0.05 vs HCl; ϕp<0.05 vs HCl+Diclofenac; arrows indicate p<0.05 between 
different groups. 
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Furthermore, cell survival is an important parameter, useful to better understand the mechanism 
that supports gastroprotection. In this context ERK/MAPK and PI3K/Akt were also analysed 
by ELISA test on hyperacidic condition. As reported in Fig. 12, Diclofenac alone induced a 
significant reduction on ERK and Akt activities, indicating a negative influence on cell survival 
(p<0.05 vs control). The pre- and post-stimulations with Aq were able to counteract these 
negative effects: indeed, ERK (p<0.05) and Akt activities (p<0.05) were significantly increased 
compared to Diclofenac, supporting previous data about the ability of Aq to act both before 
and after the damage. In addition, the major effects were observed when it was added before 
Diclofenac (about 156% and 55% respectively, compared to post-stimulation) supporting the 
hypothesized mechanism of action. On the other hand, Neo exerted a beneficial effect on ERK 
and Akt marker, but a greater result was observed when it was added after Diclofenac (about 
18% and 100%, respectively, vs pre-stimulation). All these results are important to confirm the 
different potential gastroprotective activity of Aq and Neo. 
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Fig. 12  
Analysis of survival kinases activity on hyperacid condition. In panel (a) ERK/MAPK and in 
(b) PI3K/Akt activities measured by ELISA test in gastric epithelial cells treated for 24h. 
D=Diclofenac, Aq=combination between alginates and vitamin D3, Neo=mixture of 
polysaccharides and flavonoids. All the results are expressed as means ±SD (%) normalized to 
control values of five independent experiments. *p<0.05 vs control; **p<0.05 vs HCl; ϕp<0.05 
vs HCl+Diclofenac; arrows indicate p<0.05 between different groups. 
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● 4.3 Project 3 (cardiovascular line of research) 
The results showed in this project are contained in the paper: Cooperative Effects of Q10, 
Vitamin D3, and L-Arginine on Cardiac and Endothelial Cells. Molinari C, Morsanuto V, Polli 
S, Uberti F. J Vasc Res. 2018;55(1):47-60.  
 
Effects of L -arginine, Vitamin D3 and Q10 on Cell Viability in a Time-Course Study. 
As reported in Fig. 13, Q10, L-arginine and vitD were able to stimulate cell viability on both 
cell types during time. In particular, data showed a difference between low and high 
concentrations of each substances in a dose-dependent manner and the higher concentrations 
of Q10, L-arginine and vitD have shown to have maximum effects compared to control value 
(p<0.05). In addition, these concentrations were able to induce an increase in cell viability with 
a maximum effect after 90sec of stimulation (p<0.05). This is important to demonstrate the 
physiological activation of cell viability during time. The highest concentrations of Q10, L-
arginine and vitD were used for all successive experiments and the time of stimulation was 
maintained at 90sec. 
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Fig. 13 
Time-course and dose-response study in H9c2 and PAE cells. A time-course and dose-response 
of Q10, L-arginine and VD added individually in H9c2 (column on the left) and PAE cells 
(column on the right). The concentrations reported correspond to the higher (in black) and the 
lower (in white) doses used for each substance. VD=vitamin D3 (vitD). Reported data are 
means ±SD (%) of 5 independent experiments compared to control (line). *p<0.05 vs control. 
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Effects of Co-stimulation with L-arginine, vitamin D3 and Q10 on Nitric Oxide and 
Radical Oxygen Species Production. 
Q10, L-arginine and vitD were applied together (referred to in this work as QLD) on H9c2 and 
PAE cells to demonstrate the ability of these substances to act in a cooperative manner on cell 
viability, NO and ROS release. As reported in Fig. 14A, the effect of QLD on cell viability in 
both cell types was time dependent and the maximum effect was observed at 90sec compared 
to control (75.5±0.71% in H9c2 and 88.75±0.35% in PAE cells), as previously observed with 
Q10, L-arginine and vitD individually tested. Since this study hypothesized the involvement of 
QLD in vasodilation, NO and ROS productions were also analyzed. As reported in Fig. 14B, 
NO release was time-dependent and the maximal NO release was observed at 90sec on both 
cell types (4.04±0.08 µMol in H9c2 and 2.63±0.18 µMol in PAE cells) compared to control. 
This production is comparable to the physiological release because, as shown in Fig. 14C, ROS 
production, measured at the same time, had an opposite trend; at 90sec ROS level was less than 
control on both cell types (about 42% in H9c2 and 6% in PAE cells). After this time ROS 
naturally augmented and NO decreased. In addition, the antioxidant activity of QLD was 
confirmed by the SOD activity on both cell cultures during time (Fig. 14D) in which starting 
from 90sec the stimulations were significant compared to control (p<0.05). All these findings 
have demonstrated for the first time a cooperative effect of QLD on promoting an increase in 
NO release and a possible role of these substances in vasomotility.  
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Fig. 14 
Cell viability, NO and ROS productions, and SOD activity in H9c2 and PAE cells. Time course of Q10, 
L-arginine and VD added together, here defined QLD, in H9c2 (column on the left) and PAE cells 
(column on the right). In A cell viability was shown on both cell types. Reported data are means ±SD 
(%) compared to control (0%) of 5 independent experiments. *p<0.05 vs control. In B, nitric oxide 
values assessed by Griess method on cardiac and endothelial cells are shown. Data are expressed as 
means ±SD compared to control (line 1) of 5 independent experiments. *p<0.05 vs control. In C the 
ROS production in H9c2 and PAE cells was described. Reported data are means ±SD compared to 
control (line 1) of 5 independent experiments. *p<0.05 vs control. In D the SOD activity analysis in 
H9c2 and PAE cells was described. Reported data are means ±SD (%) compared to control (0%) of 5 
independent experiments. *p<0.05 vs control. 
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Intracellular Pathways Involved in NO Release in PAE and H9c2 Cell Lines. 
The main intracellular pathways involved in vasodilation leading to eNOS activation such as 
PI3K/Akt, ERK/MAPK and other intracellular signaling such as VDR receptor and p53, were 
analyzed in both cell lines by Western blot analysis, to explain the mechanisms activated by 
QLD. As reported in Fig. 15, Q10, L-arginine and vitD alone were able to improve (p<0.05) 
the phosphorylation of Akt, ERK and eNOS at 90sec in H9c2 and similarly (p<0.05) in PAE 
cells. Data from vitD experiments confirmed previous findings on its effects on NO production. 
The results about Q10 demonstrated its ability to activate the same mechanism as vitD to exert 
its beneficial effects (p<0.05). In addition, in the samples treated with QLD, the effect on Akt, 
ERK1/2 and eNOS expressions were amplified (p<0.05) in both cell types compared to control 
(about 20%, 31% and 38% respectively in H9c2 cells; about 38%, 27% and 23% respectively 
in PAE cells). These data indicate that QLD was able to activate the intracellular pathways 
(Akt, ERK1/2) leading to eNOS activation with consequent induction of NO release from 
cardiac and endothelial cells. In addition, the importance of Akt, ERK and eNOS on NO 
production and the involvement of these mechanisms was verified using their specific 
inhibitors (wortmannin, UO16 and LNAME, respectively) in presence of QLD treatment on 
both cell types.  
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Fig. 15 
Western blot and densitometric analysis of Akt, ERK1/2 and eNOS in H9c2 and PAE cells. In each 
panel an example of Western blot of each protein was reported. In addition, the densitometric analysis 
of phosphorylation relative to specific proteins are represented at 90sec of stimulation with Q10, L-
arginine and VD added alone or together (QLD). Reported data are means ±SD (%) of 5 experiments 
compared to control (0%). VD=vitamin D3 (vitD). *p<0.05 vs control; bars indicate p<0.05 between 
QLD and the individual administration.   
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As shown in Fig. 16, the pre-treatment with the specific inhibitors caused a significant 
inhibition on NO production (p<0.05) compared to control and to QLD alone, confirming that 
QLD acts on Akt, ERK and eNOS to induce NO release. Since NO production can cause a 
damage when produced at high level, p53 was analyzed by Western blot in both cell types to 
exclude any cytotoxic effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16  
NO production measured by Griess method on cardiac and endothelial cells is shown. Data are 
expressed as means ±SD compared to control (line 1) of 5 independent experiments. *p<0.05 
vs control. The bars indicate significant (p<0.05) between QLD and specific inhibitor plus 
QLD. QLD=Q10, L-arginine and VD. wt=100nM wortmannin; UO=10µM UO126; 
LNAME=10mM Nω-nitro-L-arginine methyl ester *p<0.05 vs control; bars indicate p<0.05 
between QLD and the individual administration. 
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As reported in Fig. 17A, Q10, L-arginine and vitD individually administered did not cause any 
increase in p53 expression at 90sec of stimulation compared to control values on cardiac and 
endothelial cells; in particular, vitD induced a change of about 7% and 10% in H9c2 and PAE 
cells respectively compared to control, and Q10 of about 3% and 9% in H9c2 and PAE cells 
respectively compared to control. In addition QLD was also able to reduce the expression of 
p53 compared to control (about 11% and 12% in H9c2 and PAE cells, respectively) confirming 
its beneficial effects. Indeed, in response to low levels of oxidative stress, p53  primarily plays 
an antioxidant role without the involvement of nuclear activation. These findings demonstrate 
the importance of the cooperative activity of QLD on cardiac and endothelial cells. Since QLD 
includes vitD, an analysis on VDR receptor was considered important to define its role on the 
positive effect of QLD during vasodilation. Q10 and L-arginine alone were not able to improve 
the expression of VDR receptor (Fig. 17B) compared to control (p<0.05) in both cell types. On 
the contrary the stimulation with vitD alone was able to induce an enhancement (p<0.05) of 
VDR expression in cardiac (of about 16%) and endothelial cells (of about 38%) compared to 
control, demonstrating the effect of vitD in these cell types. In addition, the stimulation with 
QLD was able to improve this effect of about 23% in cardiac cells and 49% in endothelial ones 
compared to control and 42.5% and 30% compared to vitD alone. These findings have 
demonstrated for the first time an improvement of vitD effects caused by simultaneous 
stimulation with Q10 and L-arginine on cardiac and endothelial cells.  
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Fig. 17 
Western blot and densitometric analysis of p53 and VDR in H9c2 and PAE cells. In A and B 
densitometric analysis and Western blot of H9c2 (left) and PAE (right) cells of p53 and VDR 
at 90sec of stimulation with Q10, L-arginine and VD added alone or together (QLD). The 
images reported are an explicative example. Reported data are the means ±SD (%) of 5 
experiments compared to control (0%). VD=vitamin D3 (vitD), QLD=Q10, L-arginine and 
VD. *p<0.05 vs control; bars indicate p<0.05 between QLD and the individual administration. 
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In vivo Study on Effects of Q10, L-arginine and vitamin D3 Added Together and Alone. 
Since the cooperative effect of Q10, L-arginine and vitD acts primarily on vasodilation, these 
agents were tested either alone or added together in in vivo experiments. The single agents were 
tested in a time-course study and showed a maximal effect on aortic blood flow at 120sec of 
administration (data not shown). This treatment time was maintained for all successive 
experiments. An intravenous administration at 120sec showed an increase in aortic blood-flow 
(Fig. 18A) in a concentration-dependent manner (p<0.05) for all substances tested and in 
particular the maximum effect was obtained with the maximal concentration used (Q10 about 
61%, L-arginine about 200%, vitD about 87%) compared to control and to the minimal doses 
used (Q10 about 40%, L-arginine about 50%, vitD about 56%). These data confirm previous 
observations on cell culture experiments, about the effect of Q10, L-arginine and vitD 
individually added. In addition, data observed during SOD activity experiments on plasma 
samples (Fig. 18B) confirmed the data obtained in in vitro experiments about the antioxidant 
effect. For these findings the maximal concentration of Q10, L-arginine and vitD was used in 
all successive experiments.  
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Fig. 18 
Aortic blood flow measurements and SOD activity in rats. In A vasodilation induced at 120sec 
by dose-response tests with Q10, L-arginine and VD individually administered. Reported data 
are means ±SD (ml/min) of at least n=3 rats for each stimulation. Abbreviations are the same 
previously reported. The effect of the solvent (NaCl 0.9%) was showed as well. *p<0.05 vs 
control; bars indicate p<0.05 between different concentrations of each substances. In B, SOD 
activity on plasma sample taken at 120sec by dose-response tests with Q10, L-arginine and VD 
individually administered. *p<0.05 vs control; bars indicate p<0.05 between different 
concentrations of each substances. 
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QLD was added to demonstrate the cooperative effect during vasodilation; as reported in Fig. 
19A, QLD at 120sec can cause an increase of aortic blood flow compared to control (p<0.05) 
of about 76% and this effect was bigger than the effect of Q10, L-arginine and vitD alone of 
about 30%, 230%, 7% respectively. Moreover another important element involved in 
vasodilation, nitric oxide, was also studied under the same conditions. NO production (Fig. 
19B) induced by QLD was significant (62%, p<0.05) compared to control value and this 
production did not cause any damage because ROS production (Fig. 19C) at the same time was 
reduced (p<0.05) of about 32% compared to control. Finally, the antioxidant effect (Fig. 19D) 
of the combination of the three was confirmed by the analysis of SOD activity on plasma 
samples (p<0.05); the effect of the combination was greater than the single administration. The 
importance of cooperative effect of QLD during vasodilation was also confirmed by Western 
blot analysis (Fig. 20) in which the effect on Akt, ERK and eNOS was confirmed and higher 
than the single administrations (p<0.05). Finally, to verify the effects of QLD, some additional 
experiments were performed during ischemia-reperfusion injury (Table 2) in which QLD was 
seen to restore aortic blood flow (p<0.05 compared to ischemia). All these data have 
demonstrated for the first time a cooperative effect during vasodilation of Q10, L-arginine and 
vitD both physiological and pathological conditions. 
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Fig. 19 
QLD effects on aortic blood flow, NO and ROS production and SOD activity in plasma rats. 
Aortic blood flow (A), NO (B) and ROS (C) productions and SOD activity (D) are reported at 
120sec after intravenous administration of QLD in rats. Reported data are means ±SD of at 
least n=4 rats for each stimulation. * p<0.05 vs control. In B bars indicate p<0.05 between QLD 
and the individual administration. VD=vitamin D3 (vitD), QLD=Q10, L-arginine and VD. 
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Fig. 20 
Western blot and densitometric analysis of Akt, ERK1/2 and eNOS in aortic samples. In upper 
panel an example of Western blot and in lower panel the densitometric analysis of 
phosphorylation relative to specific proteins are reported. Data are means ±SD (%) of 5 
experiments compared to control (0%). VD=vitamin D3 (vitD), QLD=Q10, L-arginine and 
VD. *p<0.05 vs control; bars indicate p<0.05 between QLD and the individual administration.  
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 ABF (ml/min) 
Control 24.95±5.1 
Ischemia 13.9±4.5* 
QLD 21.2±3.7 ** 
 
 
Table 2 
Aortic blood flow (ABF) measured during ischemia-reperfusion experiments. Data reported 
are expressed as means±SD of almost 5 experiments (n=5 for each group). *p<0.05 vs control; 
**p<0.05 vs ischemia. 
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● 4.4 Project 4 (brain line of research) 
The results obtained are contained in the paper: Role of Combined Lipoic Acid and Vitamin D3 
on Astrocytes as a Way to Prevent Brain Ageing by Induced Oxidative Stress and Iron 
Accumulation. Molinari C, Morsanuto V, Ghirlanda S, Ruga S, Notte F, Gaetano L, Uberti F. 
Oxidative Medicine and Cellular Longevity, 2019;2019:2843121. 
 
Cell Viability under Treatments with Vitamin D3 and Lipoic Acid During Time 
MTT test was performed both in a dose-response and in a time-course study in order to assess 
the potential effect of vitD and LA alone and combined on cell viability of astrocytes. Firstly, 
in order to identify the best concentration to use, the concentration-dependent effect of LA 
alone (ranging from 10μM to 100μM) on cell viability during 24 hours (starting from 15min to 
1440min) was analyzed. 
As shown in Fig. 21a, 50μM LA appeared to be the dose able to induce the greatest effect 
(p<0.05) compared to the control and to other concentrations (10, 25, and 100μM, p<0.05) 
during all the time of stimulation, and the maximum effect of about 66% compared to the 
control was observed at 1440min. This concentration of LA was maintained for all successive 
experiments. Additional experiments were carried out to study the combination of 50μM LA 
and 100nM vitD on cell viability since the new hypothesized formulation includes LA and 
vitD. As reported in Fig. 21b, vitD increased cell viability of astrocytes in a time-course manner 
with a maximum effect, about 22% (p<0.05) at 1440min compared to the control. In addition, 
the combination of LA and vitD was able to significantly increase (p<0.05) cell viability during 
time compared to the control (p<0.05) and to 50μM LA and 100nM vitD alone starting from 
60min of stimulation (p<0.05). The combination exerted a greater effect at 1440min compared 
to the control (p<0.05) and to 50μM LA and 100nM vitD alone (about 20.5% and 64%, 
respectively). For this reason, this time of stimulation was maintained for all successive 
experiments. In conclusion, the hypothesis of the synergistic effects exerted by vitD and LA in 
astrocytes indicating a possible new strategy to slow down ageing is supported by these data. 
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Fig. 21 
Cell viability measured in time-course and dose-response studies in astrocytes. In (a), time-
course and dose-response (ranging from 10μM to 100μM) studies of LA measured in astrocytes 
are illustrated; in (b), time-course and dose-response studies of 50μM LA combined with 
100nM vitD measured in astrocytes are reported. LA=lipoic acid, vitD=vitamin D3, and 
LA+vitD=combination of lipoic acid and vitamin D3. Data are expressed as means ±SD (%) 
of five independent experiments normalized to the control (number 1 in the y axis corresponds 
to 100% control values). 
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Permeability of Vitamin D3 and Lipoic Acid through Blood-Brain Barrier (BBB) 
A BBB permeability study was performed to better understand the ability of 100nM vitD and 
50μM LA alone and combined together during time to cross the hematoencephalic barrier. As 
reported in Fig. 22a, the analysis of the basolateral volume showed a time-dependent increase 
on absorption capacity caused by 100nM vitD and 50μM LA alone compared to the control 
(p<0.05), and the greater effects were observed at 1440min (about 49.5% and 40.5%, 
respectively). The combination of vitD and LA increased the absorption capacity with respect 
to the control (p<0.05) during time and to their single administration starting from 60min, as 
previously observed on cell viability (p<0.05). These data support a cooperative effect of vitD 
and LA also during the permeability assay. The successive quantifications of vitD and LA were 
carried out to determine the specific concentration present in basolateral volume of the BBB 
model. In particular, the absorption of vitD and LA during time was time-dependent, and the 
combination of vitD and LA proved to be essential to amplify their ability to cross the barrier. 
Indeed, the specific quantifications of vitD (Fig. 22b) and LA (Fig. 22c) showed a greater effect 
of the combination compared to the separated administration (about 26% and 63%, 
respectively), with a maximum effect at 1440min (p<0.05 vs. control). In conclusion, the 
hypothesis that the combination of LA and vitD is able to exert beneficial effects directly on 
viability of astrocytes due to their ability to cross the BBB is supported by all these findings. 
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Fig. 22 
BBB permeability, vitD and LA quantifications to predict their bioavailability in the brain. In 
(a), the absorption capacity through the BBB of vitD and LA alone and combined is shown; in 
(b), quantification of vitD is shown; and in (c), quantification of LA at basolateral environment 
of the barrier model are reported. LA=lipoic acid, vitD=vitamin D3, and 
LA+vitD=combination of lipoic acid and vitamin D3. Data are expressed as means ±SD (%) 
of five independent experiments normalized to control values (0% line). 
 
 
 
 
 
100 
 
Analysis of Mitochondrial Activity after Treatments with Lipoic Acid and Vitamin D3 
in Oxidative Condition 
Cell viability, ROS production and mitochondrial potential were evaluated in astrocytes, in 
order to investigate the potential action to prevent cellular ageing under oxidative condition. 
Exposure to 200μM H2O2 significantly reduced cell viability of about 46% compared to the 
control; conversely, following posttreatment with 50μM LA and 100nM vitD alone or 
combined, the cell viability was significantly increased. The greatest effect was obtained with 
the combination of LA and vitD which reverted the cell loss (Fig. 23a). Since the main theory 
at the basis of brain ageing regards the oxidative condition, additional experiments on ROS 
production were performed. 50μM LA, 100nM vitD, and the combination of both were able to 
maintain the ROS production under the physiological level (p>0.05 vs. control), supporting the 
hypothesis of their safety during use (Fig. 23b). Exposure of astrocytes to 200μM H2O2 
significantly increased the intracellular ROS production as illustrated in Fig. 23b of about 30% 
compared to the control (p<0.05); posttreatment with 50μM LA and 100nM vitD alone 
significantly reduced ROS production (about 43% and 57%, respectively, vs. H2O2 alone), and 
the concomitant administration of LA and vitD improved the reduction of the ROS level 
compared to 200μM H2O2, 50μM LA, and 100nM vitD alone (p<0.05, about 78%, 62%, and 
50%, respectively). Since the alteration of the formation of a proton gradient across the inner 
mitochondrial membrane is considered to be one of the key indicators of cellular viability, the 
mitochondrial potential was analyzed. Treatments with 50μM LA, 100nM vitD, and with the 
combination of both induced a significant increase in red fluorescence, supporting the active 
role of 50μM LA, 100nM vitD, and their combination on mitochondrial activity (p<0.05). In 
addition, the combination of LA and vitD seems to have a greater effect compared to 50μM 
LA and 100nM vitD alone (about 23% and 60%, respectively). H2O2-treated cells exhibited 
changes in the fluorescence signal which lead to a decreased red fluorescence signal and 
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increased green fluorescence signal, indicating a significant dissipation of mitochondrial 
potential and cell loss compared to the control (p<0.05, Fig. 23c). Post-treatment with 50μM 
LA, 100nM vitD alone, and with the combination of both significantly reversed dissipation of 
mitochondrial potential as shown in Fig. 23c compared to 200μM H2O2 alone (p<0.05). In 
particular, the combination of LA and vitD suppressed the effect of H2O2-induced 
mitochondrial dissipation, shifting the fluorescence signal from green to red (p<0.05). These 
results show that the combination of LA and vitD is able to attenuates the H2O2-induced 
apoptosis through the mitochondrial-mediated pathway. 
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Fig. 23 
Analysis of cellular viability, ROS production, and mitochondrial activity under oxidative 
condition. In (a), cell viability, in (b), ROS production, and in (c), mitochondrial membrane 
potential measured on astrocytes treated with vitD and LA alone and combined for 24h pre-
stimulation with H2O2 are illustrated. LA=lipoic acid, vitD=vitamin D3, and 
LA+vitD=combination of lipoic acid and vitamin D3. Data are expressed as means ±SD (%) 
of five independent experiments normalized to control values (0% line). ∗p<0.05 vs. control; 
∗∗p<0.05 vs. LA; ϕp<0.05 vs. vitD; ϕϕp<0.05 vs. H2O2, bars: p<0.05 between treatments. 
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Study of Intracellular Pathways Activated by Lipoic Acid and Vitamin D3 in Oxidative 
Condition 
The dissipation of mitochondrial potential under oxidative condition is known to initiate a 
cascade of events leading to the activation of caspases, which in turn trigger apoptosis. In this 
context, p53 as a key factor involved in ageing, oxidative stress, and neurodegeneration and 
cytochrome C as a key regulator of both cellular energetic metabolism and apoptosis were 
investigated in astrocytes. Data reported in Fig. 24a showed a reduction on p53 activity after 
the stimulation with 50μM LA and 100nM vitD alone and in combination (p<0.05 vs. control), 
supporting previous data about the safety of the combination. p53 activity significantly 
increased in H2O2-treated astrocytes (p<0.05 vs. control), and the subsequent stimulation with 
50μM LA and 100nM vitD alone significantly reduced it (p<0.05). In addition, the combination 
of LA and vitD amplified the reduction compared to 200μM H2O2 of about 80% and the single 
administration of about 69% and 60%, respectively (p<0.05), resulting in survival-favored 
conditions. To examine the involvement of the caspase pathways, the expression of cytochrome 
C was analyzed under the same conditions. Fig. 24b and 25 show similar results for p53 under 
the stimulation with 50μM LA and 100nM vitD alone, confirming the previously observed 
beneficial effects. Supporting mitochondrial integrity, the combination of LA and vitD also 
maintained cytochrome C at the basal level. In addition, H2O2-treated cells showed an increase 
in the expression of cytochrome C which was reduced by the following stimulation with both 
50μM LA and 100nM vitD alone and combined (p<0.05). In order to exclude any oxidative 
damage induced by the stimulations, SOD3 and iNOS expressions were investigated. As 
reported in Fig. 24c, 24d and 25, the SOD3 and iNOS expressions significantly increased in 
the presence of 200μM H2O2 (p<0.05 vs. control), supporting the hypothesis of the involvement 
of oxidative stress in astrocyte death. In addition, the post-stimulation with 50μM LA and 
100nM vitD alone significantly reduced the expression of both SOD3 and iNOS compared to 
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200μM H2O2 alone, and a greater reduction was obtained by the combined stimulation with 
50μM LA and 100nM vitD compared to 200μM H2O2 (p<0.05), indicating a beneficial effect 
in counteracting the ageing process. Since the neuroinflammation is a common cause of brain 
ageing, PKA, a key anti-inflammatory marker, was also investigated under the same conditions 
(Fig. 24e and 25). The expression of PKA observed in astrocytes showed a significant increase 
in the presence of both 50μM LA and 100nM vitD alone (p<0.05), and their combination 
amplified this effect supporting the anti-inflammatory activity of LA and vitD. In the presence 
of 200μM H2O2, a significant reduction compared to the control was found, and the post-
stimulation with 50μM LA and 100nM vitD reverted the mechanism (p<0.05). The 
combination of LA and vitD added after 200μM H2O2 had a similar effect on PKA expression 
to what was observed without H2O2 indicating the ability of the combination to prevent the 
induction of inflammatory cascade under oxidative stress. A natural consequence of apoptosis 
is known to be cell loss, and the β-amyloid analysis demonstrated the alteration in brain tissue. 
As reported in Fig. 24f, the stimulation with 200μM H2O2 alone caused a significant increase 
of the APP level, supporting previous data about cell death. In addition, the post-stimulations 
with 50μM LA and 100nM vitD were able to reduce the damage as shown by the decrease in 
the APP level (p<0.05) compared to 200μM H2O2 alone. Finally, the greater effect was 
observed in the presence of the combined treatment with LA and vitD, indicating the 
effectiveness of the combination during brain damage. 
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Fig. 24 
Kinase activity and densitometric analysis of intracellular pathways involved under oxidative stress. (a) 
and (f) measurements of p53 and APP activities, respectively, measured by the ELISA test. (b–e) 
Densitometric analysis of cytochrome C, SOD3, iNOS, and p-PKA expressions obtained by analyzing 
Western blot on whole astrocyte lysates. LA=lipoic acid, vitD=vitamin D3, and LA+vitD=combination 
of lipoic acid and vitamin D3. Data are expressed as means ±SD (%) of five independent experiments 
normalized to control values (0% line) in ELISA experiments and normalized and verified on β-actin 
detection in densitometric analysis expressed as means ±SD (%). 
∗
p<0.05 vs. control; 
∗∗
p<0.05 vs. LA; 
ϕp<0.05 vs. vitD; ϕϕp<0.05 vs. H2O2, bars: p<0.05 between treatments. 
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Fig. 25 
Western blot of Cytochrome C, SOD3, iNOS, and p-PKA in astrocytes under oxidative stress. 
The images reported are an example of each protein of five independent experiments 
reproduced in triplicates. LA=lipoic acid, vitD=vitamin D3, and LA+vitD=combination of 
lipoic acid and vitamin D3. 
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The ERK/MAPK and PI3K-Akt pathways play a crucial role in the regulation of neuronal and 
brain survival. 50μM LA and 100nM vitD alone confirmed their ability to improve the viability 
of cells, activating ERK and Akt mediators, as reported in Fig. 26a and b. The combination of 
LA with vitD amplified kinase activation compared to the control and to single administration 
as well (< 0.05). Exposure to 200μM H2O2 significantly reduced ERK and Akt activities of 
about 6% and 7%, respectively, compared to the control; conversely, subsequent posttreatment 
with 50μM LA and 100nM vitD alone or combined reverted previously observed effects 
indicating the activation of survival pathways. In addition, the combination of LA with vitD 
showed a greater effect in PI3/Akt activity compared to ERK/MAPK, supporting the 
hypothesis that after the activation of Akt, all neuronal survival signaling was switched on. 
 
 
Fig. 26 
Survival kinase activities measured in astrocytes under oxidative conditions. The quantification of p-
ERK (a) and p-Akt (b) activities measured at 24h in astrocytes treated with vitD and LA alone and 
combined under pre-stimulation with H2O2 is reported. Data are reported as means ±SD (%) of five 
biological replicates normalized to control values (0% line). 
∗
p<0.05 vs. control; 
∗∗
p<0.05 vs. LA; 
ϕp<0.05 vs. vitD; ϕϕp<0.05 vs. H2O2, bars: p<0.05 between treatments. LA=lipoic acid, vitD=vitamin 
D3, and LA+vitD=combination of lipoic acid and vitamin D3. 
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Evaluation of Lipoic Acid and Vitamin D3 Activities under Iron Accumulation 
Iron can progressively be accumulated into the brain during normal ageing; in 
neurodegenerative disorders, it can be stored in abnormal accumulations. Since LA is a potent 
chelator of divalent metal ions and vitD is able to prevent the damage induced by the 
accumulation, additional experiments were performed on astrocytes to verify their protective 
ability in the brain. For this reason, cell viability and ROS production were evaluated in 
astrocytes after 6 days of stimulation, as reported in Fig. 27a and 27b. Exposure to 300μM Fe3+ 
significantly reduced cell viability of about 23% compared to the control (p < 0.05); conversely, 
following posttreatment for additional 6 days with 50μM LA and 100nM vitD alone, cell 
viability leads to control values, confirming their ability to chelate iron and repair the damage 
(p>0.05). In addition, the concomitant stimulation with LA and vitD was able to amplify the 
beneficial effect exerted by the single administration (p<0.05), supporting the idea of its 
possible helpful use during brain damage. To investigate the role of oxidation in the presence 
of iron accumulation, additional experiments on ROS production were performed. Exposure of 
astrocytes to 300μM Fe3+ for 6 days significantly increased the intracellular ROS production, 
as illustrated in Fig. 27b of about 60% compared to the control (p<0.05). Moreover, 
posttreatment for additional 6 days with 50μM LA and 100nM vitD alone significantly reduced 
ROS production (about 68% and 83%, respectively, vs. Fe3+alone), and the concomitant 
administration of LA and vitD improved the reduction of the ROS level compared to 300μM 
Fe3+ of about 92%. These findings indicate the ability of the combination to counteract the 
oxidative condition caused by iron accumulation. Since the iron accumulation is an important 
cause of brain damage, it is essential to discover strategies to prevent it; thus, some experiments 
were carried out to assess the amount of iron which remains inside the cells. As reported in Fig. 
27c, 300 μM Fe3+ increased the intracellular accumulation after 6 days of stimulation of about 
69% compared to the control (p<0.05), indicating that 6 days with an excess of iron was a 
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sufficient condition to create damage in astrocytes. The post-stimulation for additional 6 days 
with 50μM LA and 100nM vitD alone significantly reduced iron accumulation (about 81% and 
88%, respectively, vs. Fe3+alone), and the concomitant administration of LA and vitD improved 
the prevention of accumulation compared to 300μM Fe3+ of about 95% and compared to the 
single administration (p<0.05). These findings indicate the ability of the combination to 
counteract the iron-dependent damage, preventing its accumulation. 
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Fig. 27 
Cell viability, ROS production, and iron quantification in astrocytes: (a) cell viability, (b) ROS 
production, and (c) the intracellular iron quantification measured on astrocytes pretreated with 
Fe3+ for 6 days and then with vitD and LA alone or combined for additional 6 days. LA=lipoic 
acid, vitD=vitamin D3, and LA+vitD=combination of lipoic acid and vitamin D3. Data are 
expressed as means ±SD (%) of five independent experiments normalized to control values 
(0% line). ∗p<0.05 vs. control; ∗∗p<0.05 vs. LA; ϕp<0.05 vs. vitD; ϕϕp<0.05 vs. Fe3+, bars: 
p<0.05 between treatments. 
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In order to confirm the protection exerted by LA and vitD, p53 activity was analyzed as well. 
As shown in Fig. 28a, 300μM Fe3+ administration for 6 days caused a significant increase in 
p53 activity (p<0.05) compared to the control, supporting previous observations about the 
viability of cells. The post-stimulation with 50μM LA and 100nM vitD alone for additional 6 
days was able to reduce the p53 activation (p<0.05 vs. control) of about 84% and 88%, 
respectively, compared to 300μM Fe3+. Finally, the combined effect of LA with vitD for 
additional 6 days after 300μM Fe3+ was able to amplify the reduction on p53 activity (p<0.05) 
compared to 300μM Fe3+ (increased about 93%) and to the single administration (p<0.05), 
supporting the beneficial effects previously observed. The production, accumulation, and 
aggregation of APP during neurodegeneration are influenced by a number of modulators, and 
among these is iron, so the level of APP under these conditions was also detected. As illustrated 
in Fig. 28b, exposing astrocytes to 300μM Fe3+ for 6 days significantly increased the APP level 
of about 43% compared to the control (p<0.05); posttreatment for additional 6 days with 50μM 
LA and 100 nM vitD significantly reduced the APP level (about 63% and 55%, respectively, 
vs. 300μM Fe3+ alone), and the concomitant administration of LA and vitD amplified the 
reduction compared to 300μM Fe3+, 50μM LA, and 100nM vitD alone (p<0.05, about 82%, 
53%, and 61%, respectively). These findings confirm the importance of the combination to 
prevent the iron-dependent damage in the brain. Cellular oxidative stress and antioxidant 
enzyme dysregulation are linked to age-related brain degeneration, so SOD3 expression was 
investigated in the same conditions previously reported. The stimulation for 6 days with 300μM 
Fe3+ caused a significant increase in SOD3 expression (p<0.05) compared to the control which 
was reduced by the successive stimulation for 6 days more with 50μM LA or 100nM vitD alone 
(p<0.05), indicating a positive effect of 50μM LA and 100nM vitD to maintain a correct 
balance of oxidant activity in astrocytes (Fig. 28c). In addition, the combined effect of LA with 
vitD added for 6 days after 300μM Fe3+ was able to significantly reduce the expression of 
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SOD3 (p<0.05) compared to both 300μM Fe3+(about 78%) and 50μM LA and 100nM vitD 
alone (about 67% and 40%, respectively). These data allow to exclude the presence of oxidative 
damage and inflammatory cascade activation in the presence of iron accumulation, supporting 
the hypothesis that this combination could be used in human ageing. Finally, the ERK/MAPK 
activity was investigated in order to demonstrate that the combined stimulation with LA and 
vitD could prevent iron-dependent cell loss and damage, activating a rescue mechanism such 
as the survival pathways. Exposing astrocytes to 300μM Fe3+ for 6 days upregulated the 
ERK/MAPK activation as reported in Fig. 28d (p<0.05 vs. control), indicating a negative effect 
and suggesting that iron-dependent ROS generation activates this pathway; post-stimulation 
for additional 6 days with 50μM LA and 100nM vitD alone showed a significant decrease 
compared to 300μM Fe3+ (p<0.05), supporting the beneficial effects observed previously. In 
addition, the concomitant administration of LA and vitD made the observed attenuation of 
overexpression more pronounced compared to 300μM Fe3+ (p<0.05), confirming observation 
of a better survival of astrocytes after the damage. 
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Fig. 28 
Analysis of the main intracellular pathways analyzed by Western blot and the ELISA kit. In 
(a), (b), and (d), the measurements of p53, APP, and ERK/MAPK activities, respectively, are 
reported by the ELISA test. Data are expressed as means ±SD (%) of five independent 
experiments normalized to control values (0% line). (c) Densitometric analysis and Western 
blot of cytochrome SOD3 expression obtained in whole astrocyte lysates. Data are expressed 
as means ±SD (%) of five independent experiments normalized and verified on β-actin 
detection. LA=lipoic acid, vitD=vitamin D3, and LA+vitD=combination of lipoic acid and 
vitamin D3. ∗p<0.05 vs. control; ∗∗p<0.05 vs. LA; ϕp<0.05 vs. vitD; ϕϕp<0.05 vs. Fe3+, bars: 
p<0.05 between treatments. 
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5. Discussion 
This research, in its different phases, demonstrated that vitD have effects in several tissues and 
when it has been combined with other substances it is able to influence their effectiveness. 
Indeed, as regards ovarian line of research, vitD is able to improve the effects of RES in ovarian 
cells, therefore showing a cooperative effect. In particular, in CHO-K1 RES cells combined 
with the vitD showed biphasic biological effects, that is, it developed the number of viable cells 
on the one hand and was able to reduce ROS production on the other. Moreover, the 
combination can modulate in a time-dependent manner, the levels of ERK/MAPK and 
Akt/PI3K. RES acts involving ERK and Akt pathways via attenuation of ROS generation since 
it is combined with vitD. These findings confirm the antioxidant effect of RES, which is 
mediated by SOD modulation, as shown by data collected in the in vitro experiments of this 
research. As regards the biphasic response observed, the early positive effect (found at 2 min) 
is followed by a decrease is present probably due to the rapid metabolism of RES and then the 
effect on cell viability show a significant rise that last as long as 3h. Indeed, it can be 
hypothesized that an activation of long-latency intracellular metabolic pathways has occurred. 
As a matter of fact, a biphasic RES response has also been observed in other studies [257, 258]. 
The observation that beneficial effects of RES on cultured ovarian cells are enhanced by the 
co-stimulation with vitD is novel and important and it underlines the existence of a proper 
regulation essential to sustain tissue homeostasis. 
Moreover, it is noteworthy that cooperative effects exerted by combined RES and vitD have 
been made possible through the concurrent involvement of two types of receptor: ERβ and 
VDR. This finding assumes great relevance for the ovarian tropism, since it has been 
demonstrated that in the ovary, RES exhibits antiproliferative and androgen-lowering effects 
on theca-interstitial cells [259]. RES exerts a cytostatic, but not cytotoxic effect in granulosa 
cells, while inhibiting aromatization and VEGF expression [259]. In addition, RES may 
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increase the follicular reserve and extend the duration of ovarian life as an antiaging agent. 
RES studies in ovarian physiology are limited. RES was reported to exert estrogenic effects, 
increasing the uterine and ovarian weight [260, 261]. It is a phytoestrogen known to bind 
equally to estrogen receptors α and β [106, 260] and structurally similar to synthetic estrogens.  
The possibility of increasing the effectiveness of RES by associating vitD may be of clinical 
relevance in conditions linked to theca-interstitial cell hyperplasia, androgen excess and 
abnormal angiogenesis, such as PCOS, targeting most of the endocrine and metabolic 
underpinnings of PCOS. In PCOS, the typically enlarged ovaries are characterized by thecal 
and stromal hyperplasia [262]. This ovarian enlargement is associated with excessive ovarian 
androgen production and the disruption of menstrual cyclicity. Improvement of ovarian 
function, with restoration of ovulation and fertility, was observed with surgical reduction of 
ovarian size and/or partial destruction of ovarian tissues by procedures such as wedge resection 
and laparoscopic ovarian drilling [263, 264]. 
Another important information about RES is its bioavailability. The issue of bioavailability is 
determined by its rapid elimination and the fact that despite its highly effective absorption, the 
first hepatic step leaves little free RES. Indeed, only free RES can even bind to plasma proteins 
that could serve as a reservoir [93]. The in vivo phase of this research has shown that in ovarian 
tissue, RES exerts its effects in a cooperative manner with vitD. Specifically, in rat, RES in 
combination with vitD show a biphasic absorption rate not only in the ovary, but also in the 
heart, kidney and liver tissues, related to blood concentration. The combination is able to 
increase bioavailability and biodistribution and reduce ROS production confirmed by SOD 
activity. There is a modulation in a time-dependent manner of the levels of Cyclin D1 
sustaining tissue homeostasis and a cooperative effect through the involvement of the ERβ 
receptor and VDR is shown. The transport into bloodstream of RES was nonlinear during time, 
suggesting metabolism to be rate-limiting with respect to bioavailability. After the oral dose, 
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the second peak of plasma level may be due to enteric recirculation of conjugated metabolites 
by reabsorption after intestinal hydrolysis. The execution of animal experiments is justified by 
the need of studying the rate of absorption of RES. After administration, RES undergoes a 
glucuronidation. The major form of RES transferred across the rat intestinal epithelium into 
the bloodstream is its glucuronide metabolite [265]. Therefore, an efficient carrier system 
should drive RES through the epithelial stratum to the bloodstream thus shortening its 
permeation time and metabolic turnover [92]. So, it was demonstrated that the effects observed 
in in vivo experiments could be related with the previously observed in vitro effects with RES 
plus vitD. 
Another novelty in this study is the observation that the cooperative mechanism has also been 
demonstrated in the intestinal absorption phase. This is clearly stated in a new set of in vivo 
experiments where the intracellular activated cascade mechanism after absorption 
demonstrates the cooperative mechanism. It is important to note that until now it was assumed 
that the RES also acted as a VDR agonist, but primarily in anti-tumor mechanisms [112]. Due 
to its estrogenic action, RES appears to be an optimal candidate for use in gynecological 
diseases, especially in the treatment of hot flashes (HF) associated with menopause. Vasomotor 
symptoms, including the hot flush, are amongst the commonest symptoms of the menopause 
transition period. Hot flushes are a heat dissipation response characterized by flushing and 
sweating, probably triggered by a narrowing of the thermoneutral zone in the hypothalamus 
and an increased central secretion of noradrenaline. The neuroendocrine changes associated 
with a hot flush may have significance far beyond the immediate distress and discomfort 
experienced at the time [266]. Despite various therapeutic solutions for the treatment of HF 
have been proposed, the results obtained do not show evidence of effectiveness in the use of 
phytoestrogens [267]. Although there are no human studies regarding the effects of resveratrol 
on menopausal signs and symptoms, a recent trial demonstrated that resveratrol may enhance 
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mood and cognition in postmenopausal women [268]. Furthermore, vitamin D can protect 
against experimental serotonin depletion in rats [269] and a menopause-related decline in 
serotonin, a neurotransmitter with known effects on thermoregulation, may be a contributor to 
hot flashes [270-272]. In addition, estrogen increases the activity of the enzyme responsible for 
activating vitamin D [273] and so declining estrogen levels during the menopausal transition 
could lead to symptoms of vitamin D deficiency. Indeed, vitamin D supplementation can 
improve mood in non-menopausal populations [274-277]. Based on the totality of evidence 
from limited data, we hypothesized that higher levels of vitamin D would be associated with 
fewer menopause-related symptoms. 
Indeed, RES is effective in reducing the number of vasomotor episodes and the intensity of HF, 
with the transition from moderate/severe to mild symptoms in 78.6% of patients. Resveratrol 
has the characteristics to be an alternative therapy in the treatment of HF in menopause [108]. 
The scientific community is looking for innovative strategies to implement the bioavailability 
of RES through drug delivery systems such as the use of nanoemulsion-based delivery systems 
[278] or through the ability to interact in a cooperative way with other molecules such as vitD 
[279]. 
However, the interplay between resveratrol and vitamin D must be further elucidated if the true 
potential of their clinical applications is to be revealed. 
In conclusion, this part of study demonstrated for the first time a cooperative effect of RES and 
vitD on ovarian cell and tissue, mediated by main physiological intracellular mechanisms. Such 
results could be used as a fundamental data for the development of new therapies for 
gynecological conditions, such as menopause-related hot-flashes. 
As regard the part of the study inherent the role of vitamin D3 in gastric disorders, vitD showed 
a gastroprotector effect. 
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Indeed, recent clinical investigations reveal that NSAID, widely used to alleviate inflammation, 
fever, and pain in clinical practice, have an equal risk to develop gastropathic and enteropathic 
damage [121] and then the relative gastric toxicity is a major consideration [119, 280]. NSAID 
induced gastroenteropathy has emerged as an important socioeconomic problem because there 
are no approved therapeutic strategies/interventions to prevent/treat NSAID-induced 
enteropathic damage [281].  
NSAID can be divided into COX-2 selective inhibitors and non-selective COX inhibitors 
(COX1 and COX2 inhibitors) [282] which have a higher risk of ulcers in the gastrointestinal 
tract [283]. The most important non-selective COX inhibitors include aspirin, diclofenac, 
indomethacin, piroxicam, naproxen and ketoprofen [284]. Diclofenac is extensively used 
worldwide in several formulations due to its analgesic, anti-inflammatory and antipyretic 
activities [126]. Nevertheless, several side effects are consequences of their administration, 
especially with chronic use, including cardiovascular problems, renal function disorders, 
hepatic injuries, alterations in gastrointestinal mucosal integrity [122, 285] and electrolyte 
disturbances [286, 287]. A classical gastrointestinal consequence is a peptic ulcer which is a 
multifaceted process that includes the generation of ROS, inducing inflammatory molecules of 
the COX-2, cytosolic phospholipases A2, leukotriene B4, 5-lipoxygenase, PGE2, TNF-alfa, 
IL-1beta, and IL-6 production [288, 289], increasing LPO, xanthine oxidase, and DNA damage 
[290, 291] and the inhibition of antioxidant enzymes including glutathione peroxidase, 
glutathione reductase, glutathione S-transferase, catalase, superoxide dismutase, and heme 
oxygenase-1 as well as glutathione (GSH)/oxidized-GSH ratio in vivo [292]. The toxic effects 
of diclofenac on stomach mitochondria is well known [293]. Human gastric epithelial cells 
treated with diclofenac exhibited significant O2 production. Ultimately these ROS collectively 
affected the viability of the cells by striking at the basis of cellular powerhouses or 
mitochondria via mitochondrial depolarization [293]. Therefore, ROS may also cause oxidative 
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damage to biological macromolecules and react with proteins, lipids, and mitochondrial DNA, 
leading to cell death by affecting various apoptotic pathways in the gastrointestinal tract [290-
292]. Furthermore, NSAID also down-regulates angiogenesis, inhibits mucosal cellular 
restitution and promotes extracellular matrix degradation [294]. Thus, it is important to regulate 
the levels of ROS in the gastrointestinal tract. In addition, another important proinflammatory 
effect of HCl, consistent with the existing literature, is its action on synthesis [295].  
Proton pump inhibitors (PPI) are currently used for the treatment and prevention of NSAID-
induced gastroduodenal lesions [296]. The efficacy of PPI depends on their ability to inhibit 
gastric acid secretion [297]; however, in recent years, it has been proposed that acid-
independent mechanisms may also contribute to the antiulcer actions of PPI [118]. 
Additionally, there are some reports that showing how PPI may produce gastric glands toxicity 
[298] and this is associated with an appreciable amount of systemic adverse effects in humans 
[299, 300]. Thus, the identification of more effective and safer therapies for the treatment of 
NSAID-induced-gastroenteropathic lesions remains an urgent priority. For this purpose, 
researchers are still investigating new molecules to find an ideal agent with a better safety 
profile. In the current study, the effects of a new compound named Aq on an in vitro 
experimental model of gastric cells have been observed. This work demonstrates that Aq can 
exert protective effects on gastric cells in terms of viability, ROS and NO production, thanks 
to vitD, which is able to improve the beneficial effects induced by alginates, supporting existing 
data about their mechanism of gastroprotection [45, 301]. Moreover, further in vitro studies 
demonstrate that VDR activation enhances intracellular junctions and promotes mucosal 
wound repair through vitD activity [302]. There is evidence that oxidative stress plays an 
important role in the pathogenesis of gastric injury [45]. It is noteworthy that experimental 
evidence shows how ROS production or superoxide are induced both by cellular exposure to 
an alkaline environment and/or by acidic injury [303]. It is well known that vitD may prevent 
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cell death inhibiting superoxide anion generation, maintaining mitochondria function and cell 
viability, and activating survival kinases. Our results show that Aq alone, during H2O2 or HCl 
exposure is able to improve cell viability compared to control and to other commercial products 
such as Neo, composed of different natural extracts. In addition, Aq significantly reduced ROS 
production and decreased cell viability loss when added after the injury, suggesting that cell 
damage and cytotoxicity can be prevented. These results suggest that Aq may exert a better 
gastroprotective effect through an antioxidant pathway, inhibiting apoptosis and activating 
survival kinases. Such effect was stronger in preventing epithelial damage than what observed 
using other gastroprotective agents such as Neo. Since the gastroprotection is more important 
during the use of Diclofenac, further experiments were carried out to validate the observed 
results. The results obtained from this new series of experiments have allowed us to 
significantly confirm beneficial effects of Aq to prevent injury caused by diclofenac under both 
acidic and hyperacidic conditions. Indeed, the gastroprotection exerted by Aq was similar to 
effect of pantoprazole indicating its effectiveness on cell viability, on reducing ROS production 
and on apoptotic mechanism, increasing the activation of survival kinases and cell 
proliferation. 
As regards the research in cardiovascular field, the study has investigated the cooperative effect 
of Q10, L-arginine and vitD on cardiac and endothelial cells. The major results of this work 
indicate the importance of QLD on vasodilation through NO production and this effect is shown 
to be better than treatments with the individual substances. NO synthesis is involved in a 
number of cardiovascular diseases such as peripheral vascular disease, congestive heart failure 
(HF), and cerebrovascular events. An impaired NO status may cause an overproduction of ROS 
in the vasculature, including superoxide anion, hydrogen peroxide and derivative hydroxyl 
radical and hydroxide, lipid peroxides and derivatives peroxyl radicals. Q10 suppressed the 
generation of ROS, which subsequently attenuated the peroxidation and increased the 
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bioavailability of NO [168]. The results of this study have demonstrated for the first time that 
QLD is able to activate eNOS, one of three isoenzymes transforming L-arginine into L-
citrulline and NO, in cardiac and endothelial cells. This effect is time-dependent and is 
accompanied by a significant increase in the level of phosphorylation of intracellular kinases. 
Akt kinase activates eNOS by directly phosphorylating the enzyme at Ser-1179 [304]. Akt 
itself is phosphorylated and activated by PI3 kinase, which in turn is activated by various 
agonists [305]. Also MAP kinases, important mediators of signal transduction from the cell 
surface to the nucleus, have been found to modulate eNOS activation [306]. Indeed, in porcine 
aortic endothelial cells ERK, Akt pathways have recently been implicated in the effects of 
various agents on NO production [307, 230]. Data from this study clearly demonstrate that the 
administration of QLD induced the highest production of NO and acutely increased the 
phosphorylation of eNOS, Akt and ERK, which are known to be involved in the intracellular 
signaling leading to NO production [308, 309, 252]. The relationship between NO and cellular 
function is complex because NO is cytotoxic at high concentration and has a protective effect 
at low concentration [168]. The importance of Q10, L-arginine and vitD alone on the 
cardiovascular system is well known. Q10 is an integral component of the mitochondrial 
respiratory chain for ATP production as well as an antioxidant agent, thus it could assist in 
improving myocardial function in HF patients [310.]. In addition, a meta-analysis on coenzyme 
Q10 randomized clinical trials showed that it improves the outcomes of HF patients. L-arginine 
improves the endothelial function modulating the nitric oxide bioactivity, increasing 
intracellular uptake, and acting directly with antioxidant activity [153]. In epidemiological 
studies, vitD deficiency has been consistently associated with an increased risk for 
cardiovascular disease and hypertension. Disruption of vitamin D signaling in animal models 
promotes hypertension, cardiac hypertrophy, and atherosclerosis. This evidence has led to 
prospective randomized trials on vitD supplementation in individuals at risk for cardiovascular 
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disease [311]. Studies carried out on VDR knockout and 1-α hydroxylase-deficient mouse 
models showed elevated arterial blood pressure [52, 53].  
Other studies carried out on spontaneous hypertensive rats have indicated that vitamin D3 
administration suppresses endothelium-dependent contraction of aorta in these models [312, 
313]. Vitamin D3 has antihypertrophic, anti-inflammatory and antiproliferative properties and 
may reduce cardiac hypertrophy in spontaneous hypertensive rats [182]. Furthermore, vitamin 
D3 has a direct effect on endothelial and smooth muscle cells and may decrease coagulation 
and increase re-epithelialization and fibrinolysis [182]. 
In the animal model as well as in cell lines we have investigated the effects of antioxidant 
therapy with Q10, L-arginine and vitD to improve endothelial and cardiac function by means 
of a VDR-mediated reduction in ROS production. This finding is supported by the fact that 
VDR is expressed throughout the myocardium on various cell types including cardiomyocytes 
and endothelial cells [252, 314]. QLD was able to maintain the ability of vitD to induce its 
beneficial effects on cardiovascular system whereas vitD supports the effects of Q10 during 
vasodilation as a consequence on L-arginine effect. In addition the positive effects exerted by 
QLD were demonstrated thanks to a reduction of p53 activation and ROS production on both 
cell types. Indeed, the level of ROS observed at 300sec was not enough to cause tissue damage 
and always remained under physiological range. Since the translational approach is very 
important to confirm the mechanisms observed in vitro, some experiments were performed in 
an in vivo model. In rats the beneficial effects on vasodilation of Q10, L-arginine and vitD 
added together have been confirmed and compared to these substances alone. In addition the 
effects of QLD on vasodilation were demonstrated through the increase of NO production.  
All these data confirm the importance of Q10, L-arginine and vitD during vasodilation and 
demonstrate for the first time a possible cooperative use in amplifying the positive effect of 
each of them. Using QLD to counteract increased free radical production is a potential method 
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to reduce myocardial injury in patients and to reduce aging effects on the heart. This is relevant 
in the light of the possible use of QLD supplementation as a potential tool to treat or prevent 
cardiovascular diseases. 
In addition, as regards the research part focused on vitamin D3 in brain ageing, several studies 
were conducted which shows the association between vitamin D and brain health and the 
impact of vitamin D deficiency on the brain. In 2016, Miller BJ et al. conducted a human study 
which shows that vitamin D increases plasma Aβ in older adults, indicative of decreased brain 
Aβ [315]. Annweiler C et al. conducted a study which demonstrates the neurosteroid actions 
of vitamin D in the regulation of calcium homeostasis, β-amyloid deposition, antioxidant and 
anti-inflammatory properties. It also discusses neuroprotection action of vitamin D against 
neurodegenerative process associated with Alzheimer’s disease and cognition [316]. 
Furthermore, a study conducted by Annweiler et al. shows that hypovitaminosis D is commonly 
seen in adults and 65-year-old patients. They show sign of dementia and cognition impairment 
[317]. Also in early life vitamin D plays a vital role in neuronal development. Some studies 
conducted recently shows the effect of vitamin D on early life brain development. A study 
conducted by Yates et al. shows that deficiency of vitamin D in maternal and offspring causes 
some disabilities in early life including learning and memory problems and grooming 
behaviours. There was also some evidence of increased lateral ventricle volume and altered 
neural expression of genes involved in dopamine and glucocorticoid-related pathways 
suggesting autism and schizophrenic-like disorders [318]. 
Di Somma et al., shows optimal levels of vitamin D in the bloodstream are necessary to 
preserve the neurological development and protect the adult brain [319]. Balanced dietary 
intake is a well-established lifestyle factor in maintaining cognition during ageing. A recent 
study shows that vitamin D helps in keeping cognitive function in older adults [320]. 
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Furthermore, recent studies hypothesize also the use of antioxidant molecules combined with 
symptomatic drugs to reduce oxidative stress, thus improving cognitive functions during 
ageing and in age-related diseases [321]. It is well known that the brain is highly susceptible to 
oxidative damage due to high concentrations of polyunsaturated fatty acids and transition of 
metals that are involved in the generation of the hydroxyl radical [322, 323]. In an adult brain, 
astrocytes are responsible in maintaining neuronal and synaptic functions [324] and the 
oxidative stress plays a key role in astrocyte loss, mainly due to the highly active mitochondria 
metabolism [323]. 
According to literature, the brain has a poor catalytic activity and has low levels of protective 
antioxidant enzymes; for this reason, in this part of research, the efficacy of LA and vitD in 
oxidative mechanisms involved in the ageing process was tested. Indeed, it was demonstrated 
that the combination of LA and vitD exerts a synergistic and cooperative effect on astrocyte 
activity indicating a possible new strategy to slow down ageing. The combination of LA and 
vitD is able to perform beneficial effects directly on viability of astrocytes, since these 
substances are able to cross the blood-brain barrier. Moreover, the combination of LA and vitD 
increases the absorption rate of the two substances compared to the control during time and to 
their single administration starting from 60min, supporting the cooperative effects of LA and 
vitD also during permeability. A recent work by Farr et al. [325] demonstrated that lipoic acid 
improves memory and reverses indices of oxidative stress in old mice but decreases the 
lifespan. This feature has not been studied in this research. This could be a limitation of this 
research, which could be addressed in the future. However, vitD, with its antioxidant action, 
allows to use lower doses of lipoic acid, and this could improve the safety of the molecule. 
Another limitation of this study could be the use of HUVEC rather than a brain-derived 
endothelial cell. However, some studies indicate that this experimental model can present 
structural and functional equivalency with in vivo BBB while still using HUVEC [326]. 
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Oxidative stress has a key role in ageing and for this reason additional experiments on ROS 
production were performed. Treatment with LA and vitD improves the reduction of the ROS 
level in oxidative conditions. The alteration of the formation of a proton gradient across the 
inner mitochondrial membrane is considered to be one of the key indicators of cellular viability; 
the combination of LA and vitD suppressed the effect of H2O2-induced mitochondrial 
dissipation. Thus, this study demonstrates that combined LA and vitD can attenuate the H2O2-
induced apoptosis through the mitochondrial-mediated pathways. Furthermore, the specifics to 
be used in combination have been determined evaluating the intracellular pathways activated 
by LA and vitD during oxidative condition. Our findings suggest that there is a reduction on 
p53 activity after the stimulation with LA and vitD that it is correlated to survival-favored 
conditions. Moreover, the involvement of the caspase pathway has been examined analyzing 
the expression of cytochrome C. The combination of LA and vitD is able to reduce cytochrome 
C expression during oxidative damage, supporting mitochondrial integrity. Besides, it has been 
demonstrated that stimulation with LA and vitD under oxidative condition can reduce cell death 
and increase cell survival, by the activation of ERK and Akt mediators. Even the major 
pathways (SOD3 and iNOS) involved in oxidative stress were inhibited by administration of 
LA and vitD, indicating better cell survival. 
Since neuroinflammation is a common cause of brain ageing, PKA, a key anti-inflammatory 
marker, was also investigated under the same conditions. The cAMP-dependent PKA signaling 
is one of the best-characterized signal transduction mechanisms in the central nervous system 
[327] and plays a diverse role in neuronal functions, such as regulating synaptic plasticity, 
learning, and memory [328]. PKA is a key phosphorylating enzyme, which triggers a wide 
variety of physiological involvement in cell survival, synaptic plasticity, and activation or 
repression of gene expression [327]. The PKA role in inflammation consists in its involvement 
in the cross talk between different signaling mechanisms such as the inactivation of 
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phospholipase Cβ; the phosphorylation of inositol 1,4,5-tris phosphate receptors, thereby 
modulating Ca2+ influx; and the phosphorylation of calcium-calmodulin kinase. In addition, 
cAMP stimulates mitogen-activated protein kinase activity in cultured neurons [327]. In 
addition, some studies by Salinthone et al. demonstrated that cAMP/PKA inhibits NF-κB 
function by slowing down its translocation into the nucleus and inhibits NF-κB activity [329]. 
The expression of PKA observed in astrocytes showed a significant increase in the presence of 
LA and vitD, and their combination amplified this effect, supporting the hypothesis of an anti-
inflammatory activity of combined LA and vitD. The combination of LA and vitD added after 
H2O2 had a similar effect on PKA expression. This finding allows to exclude the involvement 
of inflammation cascade during treatment with LA and vitD combined. 
Neuroinflammation and iron accumulation are hallmarks of a variety of adult 
neurodegenerative diseases [330], and particularly, iron is recognized to influence the 
biochemistry of proteins involved in neurodegeneration (for instance, APP), as well as those 
playing a crucial role in neuronal development and efficiency [331]. Moreover, it was 
demonstrated that the exposure to Fe3+ significantly reduced cell viability and increased ROS 
production and the combination of LA and vitD can prevent Fe3+-dependent oxidative injury 
in astrocytes. It is well known that LA is a potent chelator of divalent metal ions and vitD is 
able to prevent the damage induced by the iron accumulation [242, 332]. However, processes 
involved in age-related and disease-related accumulations of iron and iron-induced 
inflammation in specific brain regions and cells are poorly understood. Post-treatment with LA 
and vitD was able to restore the damage caused by iron accumulation. Furthermore, it has been 
demonstrated that LA and vitD alone or together were able to prevent intracellular iron 
accumulation damage by their ability to prevent iron deposition promoting its elimination (in 
fact, the treatment was added after 6 days of iron administration). Besides, even if the presence 
of iron caused a harmful condition for the cells, the response to treatment significantly activated 
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the cellular survival mechanisms (ERK) by switching off apoptosis mechanisms (p53). Indeed, 
these effects were found to be mediated by the inhibiting effect of LA on oxidative (SOD3) 
and inflammatory (APP) systems. 
In conclusion, this study demonstrates for the first time that the combination of LA and vitD is 
an effective treatment for astrocytes under oxidative stress conditions, indicating the possibility 
of developing new strategies to treat brain ageing in all stages. Besides, the combined treatment 
with LA and vitD improved the negative effects of pre-neurodegenerative conditions, so there 
are the preludes to develop a new formulation to slow down brain ageing and 
neurodegenerative diseases, like Alzheimer and Parkinson diseases, such as a new food 
supplement Cebral®. 
Vitamin D, has long been known to help build strong bones by increasing the body's absorption 
of calcium and phosphorous. But beginning in 2000, research into vitamin D's role in other 
health conditions began to expand rapidly especially due to the presence of its receptor (VDR) 
in many tissues and organs. The role of vitamin D in calcium metabolism has been extensively 
studied and there is strong support for vitamin D's role in bone health. However, it is showing 
surprising effects distributed throughout the body and the study of the extraskeletal role of 
vitamin D has become a very promising line of research in recent years. This thesis fits 
perfectly into the category of research aimed at developing new therapeutic applications that 
can be foreseen for this precious molecule. 
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6. Future Perspective 
Since vitamin D deficiency is usually associated with several human disease, further studies 
should be performed in order to verify if the correct dosage and use of vitamin D 
supplementation can improve the quality of life of subjects. In this context, many researchers 
proposed to use vitamin D3 and/or its derivatives at low dosage combined with other 
substances, such as natural compounds to potentiate their beneficial effects and not the toxicity 
one. For instance, plant polyphenols, e.g., carnosic acid (CA) from rosemary and silibinin from 
milk thistle, markedly potentiate the differentiation-inducing effects of low concentrations of 
Vitamin D and its derivatives on AML cell lines and patient-derived leukemic blasts [333]. 
Indeed, in recent years there is a growing interest in the study of natural substances to support 
the health of the body; the use of natural substances it is mainly used for the treatment of 
phlogistic states, but also in other pathologies such as senile dementia, peptic ulcer and 
gastrointestinal disorders, prostatic hypertrophy, memory loss, beneficial effects can be 
observed. In addition, these substances are able to strengthen the immune system and reduce 
plasma cholesterol levels. [334]. For example, studies have shown that diet-ingested 
polyphenols are associated with  reduce risk in some chronic diseases including cardiovascular 
disease, neurodegenerative disorders, diabetes, cancer and osteoarthritis [335]. Another 
interesting example regards curcumin which is the active substance contained in turmeric, well 
known for its antioxidant action, anti-inflammatory and modulatory effect on the main enzymes 
involved in the regulation of the cellular cycle [336]. The protective effects are expressed on 
different tissues and include cardiovascular protection, hepatoprotection and protection from 
gastric ulcers [337]. Thanks to experimental studies, the food industry has also recently focused 
its attention on plants and fruits with a high polyphenol content and is introducing many 
functional foods and dietary supplements onto the market. [338]. Polyphenols have antioxidant 
and anti-inflammatory capacities, that are able to protect cells from oxidative stress and to keep 
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cholesterol levels within physiological limits. Moreover, they also have antibacterial, 
antipruritic, antiparasitic and cytotoxic properties. 
For this reason, the study of an alternative strategy for the development of a new vitamin D-
based therapy that passes through the enhancement of its activity by associating other 
compounds seems to be particularly promising. The combination of these agents of different 
molecular classes has led in various experimental systems and clinical protocols to greater 
efficacy than the compounds administered individually. Some compounds of plant origin and 
antioxidants and also some compounds that do not belong to these groups, but which have 
potential as co-inductors of vitamin D3, will be studied in the near future in order to improve 
the knowledge of this vitamin and its combined effects in different conditions for develop some 
possible new therapeutic strategies for humans. 
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